499 results on '"Dossus,L"'
Search Results
52. Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - results from the EPIC cohort
- Author
-
Kaaks, R, Tikk, K, Sookthai, D, Schock, H, Johnson, T, Tjønneland, A, Olsen, A, Overvad, K, Clavel-Chapelon, F, Dossus, L, Baglietto, L, Rinaldi, S, Chajes, V, Romieu, I, Boeing, H, Schütze, M, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Sieri, S, Tumino, R, Ricceri, F, Mattiello, A, and Buckland, G
- Abstract
Results from prospective studies on premenopausal serum hormone levels in relation to breast cancer risk have been inconclusive, especially with regard to tumor subtypes. Using a case-control study nested within the prospective European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (801 breast cancer cases and 1,132 matched control subjects), we analyzed the relationships of prediagnostic serum estradiol, free estradiol, progesterone, testosterone, free testosterone and sex hormone-binding globulin (SHBG) levels with the risk of breast cancer by estrogen and progesterone receptor-positive and -negative breast tumors and by age at diagnoses. Higher prediagnostic serum levels of testosterone and free testosterone were associated with an increased overall risk of breast cancer [ORQ4-Q1 = 1.56 (95% CI 1.15-2.13), ptrend = 0.02 for testosterone and ORQ4-Q1 = 1.33 (95% CI 0.99-1.79), ptrend = 0.04 for free testosterone], but no significant risk association was observed for estradiol, free estradiol, progesterone and SHBG. Tests for heterogeneity between receptor-positive and -negative tumors were not significant. When analysis were stratified by age at tumor diagnosis, the odds ratios observed for estradiol were stronger and borderline significant for breast cancer diagnosed at age less than 50 [ORQ4-Q1 = 1.32 (95% CI 0.87-2.01), ptrend = 0.05] compared to breast cancer diagnosed at age 50 or above [ORQ4-Q1 = 0.94 (95% CI 0.60-1.47), ptrend = 0.34, phet = 0.04]. In conclusion, our data indicate that higher premenopausal circulating testosterone levels are associated with an increased risk of developing breast cancer, but do not show a significant association of estradiol or progesterone with breast cancer risk, overall, by menstrual cycle phase or by tumor receptor status, although a possible risk increase with higher estradiol levels for tumors diagnosed before age 50 was seen.
- Published
- 2016
53. Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Ose, J, Fortner, RT, Rinaldi, S, Schock, H, Overvad, K, Tjonneland, A, Hansen, L, Dossus, L, Fournier, A, Baglietto, L, Romieu, I, Kuhn, E, Boeing, H, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Masala, G, Sieri, S, Tumino, R, Sacerdote, C, Mattiello, A, Ramon Quiros, J, Obón-Santacana, M, and Larrañaga, N
- Abstract
The role of endogenous androgens and sex hormone-binding globulin (SHBG) in ovarian carcinogenesis is poorly understood. Epithelial invasive ovarian cancer (EOC) is a heterogeneous disease and there are no prospective data on endogenous androgens and EOC risk by tumor characteristics (histology, grade, stage) or the dualistic model of ovarian carcinogenesis (i.e. type I vs. type II, leading to less or more aggressive tumors). We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort evaluating androgens and SHBG and invasive EOC risk by tumor characteristics. Female participants who provided a blood sample and were not using exogenous hormones at blood donation were eligible (n = 183,257). A total of 565 eligible women developed EOC; two controls (n = 1,097) were matched per case. We used multivariable conditional logistic regression models. We observed no association between androgens, SHBG and EOC overall. A doubling of androstenedione reduced risk of serous carcinomas by 21% (odds ratio (OR)log2 = 0.79, 95% confidence interval [CI] = [0.64-0.97]). Moreover, associations differed for low-grade and high-grade carcinomas, with positive associations for low-grade and inverse associations for high-grade carcinomas (e.g. androstenedione: low grade: ORlog2 = 1.99 [0.98-4.06]; high grade: ORlog2 = 0.75 [0.61-0.93], phet ≤ 0.01), similar associations were observed for type I/II tumors. This is the first prospective study to evaluate androgens, SHBG and EOC risk by tumor characteristics and type I/II status. Our findings support a possible role of androgens in ovarian carcinogenesis. Additional studies exploring this association are needed.
- Published
- 2016
54. Prediagnostic plasma testosterone, sex hormone-binding globulin, IGF-I and hepatocellular carcinoma: etiological factors or risk markers?
- Author
-
Lukanova, A, Becker, S, Hüsing, A, Schock, H, Fedirko, V, Trepo, E, Trichopoulou, A, Bamia, C, Lagiou, P, Benetou, V, Trichopoulos, D, Nöthlings, U, Tjønneland, A, Overvad, K, Dossus, L, Teucher, B, Boeing, H, Aleksandrova, K, Palli, D, Pala, V, Panico, S, Tumino, R, Ricceri, F, Bueno-de-Mesquita, H, and Siersema, P
- Abstract
Elevated prediagnostic testosterone and insulin-like growth factor I (IGF-I) concentrations have been proposed to increase risk of hepatocellular carcinoma (HCC). However, the metabolism of these hormones is altered as a consequence of liver damage and they may have clinical utility as HCC risk markers. A case-control study was nested within the European Prospective Investigation into Cancer and Nutrition cohort and included 125 incident HCC cases and 247 individually matched controls. Testosterone, sex hormone-binding globulin (SHBG) and IGF-I were analyzed by immunoassays. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by conditional logistic regression. The area under the receiver operating curves (AUC) was calculated to assess HCC predictive ability of the tested models. After adjustments for epidemiological variables (body mass index, smoking, ethanol intake, hepatitis and diabetes) and liver damage (a score based on albumin, bilirubin, aspartate aminotransaminase, alanine aminotransaminase, gamma-glutamyltransferase and alkaline phosphatase concentrations), only SHBG remained significantly associated with risk [OR for top versus bottom tertile of 3.86 (1.32-11.3), p(trend) = 0.009]. As a single factor SHBG had an AUC of 0.81 (0.75-0.86). A small, but significant increase in AUC was observed when SHBG was added to a model including the liver damage score and epidemiological variables (from 0.89 to 0.91, p = 0.02) and a net reclassification of 0.47% (0.45-0.48). The observed associations of HCC with prediagnostic SHBG, free testosterone and IGF-I concentrations are in directions opposite to that expected under the etiological hypotheses. SHBG has a potential to be tested as prediagnostic risk marker for HCC.
- Published
- 2016
55. Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: A nested case-control study
- Author
-
Kühn, T, Kaaks, R, Becker, S, Eomois, P, Clavel-Chapelon, F, Kvaskoff, M, Dossus, L, Tjønneland, A, Olsen, A, Overvad, K, Chang-Claude, J, Lukanova, A, Buijsse, B, Boeing, H, Trichopoulou, A, Lagiou, P, Bamia, C, Masala, G, Krogh, V, Sacerdote, C, Tumino, R, Mattiello, A, Buckland, G, Sánchez, M, and Menéndez, V
- Abstract
Experimental evidence suggests that vitamin D might play a role in the development of breast cancer. Although the results of case-control studies indicate that circulating 25-hydroxyvitamin D [25(OH)D] is inversely associated with the risk of breast cancer, the results of prospective studies are inconsistent. A case-control study embedded in the European Prospective Investigation into Cancer and Nutrition (EPIC) was carried out comprising 1,391 incident breast cancer cases and 1,391 controls. Multivariable conditional logistic regression models did not reveal a significant overall association between season-standardized 25(OH)D levels and the risk of breast cancer (ORQ4-Q1 [95% CI]: 1.07 [0.85-1.36], ptrend = 0.67). Moreover, 25(OH)D levels were not related to the risks of estrogen receptor positive tumors (ORQ4-Q1 [95% CI]: 0.97 [0.67-1.38], p trend = 0.90) and estrogen receptor negative tumors (OR Q4-Q1 [95% CI]: 0.97 [0.66-1.42], ptrend = 0.98). In hormone replacement therapy (HRT) users, 25(OH)D was significantly inversely associated with incident breast cancer (ORlog2 [95% CI]: 0.62 [0.42-0.90], p = 0.01), whereas no significant association was found in HRT nonusers (ORlog2 [95% CI]: 1.14 [0.80-1.62], p = 0.48). Further, a nonsignificant inverse association was found in women with body mass indices (BMI) < 25 kg/m2 (ORlog2 [95% CI]: 0.83 [0.67-1.03], p = 0.09), as opposed to a borderline significant positive association in women with BMI ≥ 25 kg/m2 (ORlog2 [95% CI]: 1.30 [1.0-1.69], p = 0.05). Overall, prediagnostic levels of circulating 25(OH)D were not related to the risk of breast cancer in the EPIC study. This result is in line with findings in the majority of prospective studies and does not support a role of vitamin D in the development of breast cancer. What's new? Experimental studies have indicated that vitamin D may play a role in preventing tumor formation in the breast. However, in the present investigation, the largest prospective case-control study on circulating 25-hydroxyvitamin D (25(OH)D) and breast cancer risk conducted to date, pre-diagnostic levels of 25(OH)D were found to be unrelated to overall breast cancer risk. While the results support those of similar prospective studies, a significant inverse association was detected between 25(OH)D levels and incident breast cancer in women taking hormone replacement therapy, suggesting that background factors may influence risk associations. © 2013 UICC.
- Published
- 2016
56. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer
- Author
-
Aleksandrova, K, Boeing, H, Nöthlings, U, Jenab, M, Fedirko, V, Kaaks, R, Lukanova, A, Trichopoulou, A, Trichopoulos, D, Boffetta, P, Trepo, E, Westhpal, S, Duarte-Salles, T, Stepien, M, Overvad, K, Tjønneland, A, Halkjaer, J, Boutron-Ruault, M, Dossus, L, Racine, A, Lagiou, P, Bamia, C, Benetou, V, Agnoli, C, and Palli, D
- Abstract
Obesity and associated metabolic disorders have been implicated in liver carcinogenesis; however, there are little data on the role of obesity-related biomarkers on liver cancer risk. We studied prospectively the association of inflammatory and metabolic biomarkers with risks of hepatocellular carcinoma (HCC), intrahepatic bile duct (IBD), and gallbladder and biliary tract cancers outside of the liver (GBTC) in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Over an average of 7.7 years, 296 participants developed HCC (n=125), GBTC (n=137), or IBD (n=34). Using risk-set sampling, controls were selected in a 2:1 ratio and matched for recruitment center, age, sex, fasting status, and time of blood collection. Baseline serum concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), C-peptide, total high-molecular-weight (HMW) adiponectin, leptin, fetuin-a, and glutamatdehydrogenase (GLDH) were measured, and incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression. After adjustment for lifestyle factors, diabetes, hepatitis infection, and adiposity measures, higher concentrations of CRP, IL-6, C-peptide, and non-HMW adiponectin were associated with higher risk of HCC (IRR per doubling of concentrations=1.22; 95% CI=1.02-1.46; P = 0.03; 1.90; 95% CI=1.30-2.77; P = 0.001; 2.25; 95% CI=1.43-3.54; P = 0.0005; and 2.09; 95% CI=1.19-3.67; P = 0.01, respectively). CRP was associated also with risk of GBTC (IRR=1.22; 95% CI=1.05-1.42; P = 0.01). GLDH was associated with risks of HCC (IRR=1.62; 95% CI=1.25-2.11; P = 0.0003) and IBD (IRR=10.5; 95% CI=2.20-50.90; P = 0.003). The continuous net reclassification index was 0.63 for CRP, IL-6, C-peptide, and non-HMW adiponectin and 0.46 for GLDH, indicating good predictive ability of these biomarkers. Conclusion: Elevated levels of biomarkers of inflammation and hyperinsulinemia are associated with a higher risk of HCC, independent of obesity and established liver cancer risk factors. © 2014 The Authors. Hepatology published by Wiley on behalf of the American Association for the Study of Liver Diseases.
- Published
- 2016
57. Active and passive cigarette smoking and breast cancer risk: results from the EPIC cohort
- Author
-
Dossus, L, Boutron-Ruault, M, Kaaks, R, Gram, I, Vilier, A, Fervers, B, Manjer, J, Tjonneland, A, Olsen, A, Overvad, K, Chang-Claude, J, Boeing, H, Steffen, A, Trichopoulou, A, Lagiou, P, Sarantopoulou, M, Palli, D, Berrino, F, Tumino, R, Vineis, P, Mattiello, A, Bueno-de-Mesquita, H, van Duijnhoven, F, Bakker, M, and Peeters, P
- Abstract
Recent cohort studies suggest that increased breast cancer risks were associated with longer smoking duration, higher pack-years and a dose-response relationship with increasing pack-years of smoking between menarche and first full-term pregnancy (FFTP). Studies with comprehensive quantitative life-time measures of passive smoking suggest an association between passive smoking dose and breast cancer risk. We conducted a study within the European Prospective Investigation into Cancer and Nutrition to examine the association between passive and active smoking and risk of invasive breast cancer and possible effect modification by known breast cancer risk factors. Among the 322,988 women eligible for the study, 9,822 developed breast cancer (183,608 women with passive smoking information including 6,264 cases). When compared to women who never smoked and were not being exposed to passive smoking at home or work at the time of study registration, current, former and currently exposed passive smokers were at increased risk of breast cancer (hazard ratios (HR) [95% confidence interval (CI)] 1.16 [1.05-1.28], 1.14 [1.04-1.25] and 1.10 [1.01-1.20], respectively). Analyses exploring associations in different periods of life showed the most important increase in risk with pack-years from menarche to FFTP (1.73 [1.29-2.32] for every increase of 20 pack-years) while pack-years smoked after menopause were associated with a significant decrease in breast cancer risk (HR = 0.53, 95% CI: 0.34-0.82 for every increase of 20 pack-years). Our results provide an important replication, in the largest cohort to date, that smoking (passively or actively) increases breast cancer risk and that smoking between menarche and FFTP is particularly deleterious.
- Published
- 2016
58. Prediagnostic plasma testosterone, sex hormone-binding globulin, IGF-I and hepatocellular carcinoma: etiological factors or risk markers?
- Author
-
Lukanova, A, Becker, S, Hüsing, A, Schock, H, Fedirko, V, Trepo, E, Trichopoulou, A, Bamia, C, Lagiou, P, Benetou, V, Trichopoulos, D, Nöthlings, U, Tjønneland, A, Overvad, K, Dossus, L, Teucher, B, Boeing, H, Aleksandrova, K, Palli, D, Pala, V, Panico, S, Tumino, R, Ricceri, F, Bueno-de-Mesquita, HB, Siersema, PD, Peeters, PH, Quiros, JR, Duell, EJ, Molina-Montes, E, Chirlaque, MD, Gurrea, AB, Dorronsoro, M, Lindkvist, B, Johansen, D, Werner, M, Sund, M, Khaw, KT, Wareham, N, Key, TJ, Travis, RC, Rinaldi, S, Romieu, I, Gunter, MJ, Riboli, E, Jenab, M, Kaaks, R, Lukanova, A, Becker, S, H?sing, A, Schock, H, Fedirko, V, Trepo, E, Trichopoulou, A, Bamia, C, Lagiou, P, Benetou, V, Trichopoulos, D, N?thlings, U, Tj?nneland, A, Overvad, K, Dossus, L, Teucher, B, Boeing, H, Aleksandrova, K, Palli, D, Pala, V, Panico, Salvatore, Tumino, R, Ricceri, F, Bueno de Mesquita, Hb, Siersema, Pd, Peeters, Ph, Quiros, Jr, Duell, Ej, Molina Montes, E, Chirlaque, Md, Gurrea, Ab, Dorronsoro, M, Lindkvist, B, Johansen, D, Werner, M, Sund, M, Khaw, Kt, Wareham, N, Key, Tj, Travis, Rc, Rinaldi, S, Romieu, I, Gunter, Mj, Riboli, E, Jenab, M, and Kaaks, R.
- Subjects
Aged, 80 and over ,Male ,Carcinoma, Hepatocellular ,Liver Neoplasms ,Enzyme-Linked Immunosorbent Assay ,Middle Aged ,ROC Curve ,Risk Factors ,Area Under Curve ,Case-Control Studies ,Sex Hormone-Binding Globulin ,Biomarkers, Tumor ,Humans ,Female ,Testosterone ,Insulin-Like Growth Factor I ,Aged - Abstract
Elevated pre-diagnostic testosterone and insulin-like growth factor-I (IGF-I) concentrations have been proposed to increase risk of hepatocellular carcinoma (HCC). However, the metabolism of these hormones is altered as a consequence of liver damage and they may have clinical utility as HCC risk markers. A case-control study was nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort and included 125 incident HCC cases and 247 individually matched controls. Testosterone, sex hormone binding globulin (SHBG) and IGF-I were analyzed by immunoassays. Odds ratios (OR) and 95% confidence intervals (CI) were estimated by conditional logistic regression. The area under the receiver operating curves (AUC) was calculated to assess HCC predictive ability of the tested models. After adjustments for epidemiological variables (body mass index, smoking, ethanol intake, hepatitis and diabetes) and liver damage (a score based on albumin, bilirubin, aspartate aminotransaminase, alanine aminotransaminase, gamma-glutamyltransferase and alkaline phosphatase concentrations), only SHBG remained significantly associated with risk (OR for top versus bottom tertile of 3.86 (1.32-11.3), ptrend =0.009). As a single factor SHBG had an AUC of 0.81 (0.75-0.86). A small, but significant increase in AUC was observed when SHBG was added to a model including the liver damage score and epidemiological variables (from 0.89 to 0.91, p=0.02) and a net reclassification of 0.47% (0.45-0.48). The observed associations of HCC with pre-diagnostic SHBG, free testosterone and IGF-I concentrations are in directions opposite to that expected under the etiological hypotheses. SHBG has a potential to be tested as pre-diagnostic risk marker for HCC. © 2013 Wiley Periodicals, Inc.
- Published
- 2014
59. Healthy Lifestyle and Risk of Cancer in the European Prospective Investigation Into Cancer and Nutrition Cohort Study
- Author
-
McKenzie, F, Biessy, C, Ferrari, P, Freisling, H, Rinaldi, S, Chajès, V, Dahm, C, Overvad, K, Dossus, L, Lagiou, P, Trichopoulos, D, Trichopoulou, A, Bueno-de-Mesquita, H, May, A, Peeters, P, Weiderpass, E, Sanchez, M, Navarro, C, Ardanaz, E, Ericson, U, Wirfält, E, Travis, R, Romieu, I, de Batlle, J, Dartois, L, Krogh, V, Panico, S, Tumino, R, Rosso, S, Buckland, G, Andersson, A, Sund, M, Key, T, Gunter, M, Riboli, E, Vergnaud, A, and Medical Research Council (MRC)
- Subjects
Gerontology ,Male ,Health Status ,GUIDELINES ,0302 clinical medicine ,Behavior Therapy ,Neoplasms ,Medicine ,030212 general & internal medicine ,Prospective Studies ,Prospective cohort study ,Non-U.S. Gov't ,INDEX ,Cancer ,Medicine(all) ,education.field_of_study ,VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801 ,Nutritional Support ,Research Support, Non-U.S. Gov't ,Hazard ratio ,Age Factors ,WOMEN ,General Medicine ,Middle Aged ,Nutrition Surveys ,Prognosis ,3. Good health ,European Prospective Investigation into Cancer and Nutrition ,Europe ,Multicenter Study ,030220 oncology & carcinogenesis ,Cohort ,Female ,CONCORDANCE ,Life Sciences & Biomedicine ,RESEARCH FUND/AMERICAN INSTITUTE ,Cohort study ,Research Article ,Adult ,Population ,Observational Study ,Lower risk ,Research Support ,Risk Assessment ,DIET ,03 medical and health sciences ,Medicine, General & Internal ,Sex Factors ,General & Internal Medicine ,Journal Article ,Humans ,CORONARY-HEART-DISEASE ,education ,Life Style ,METAANALYSIS ,Science & Technology ,Cancer prevention ,business.industry ,Prevention ,1103 Clinical Sciences ,PREVENTION ,Arthritis & Rheumatology ,Life style ,VDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801 ,business ,Demography ,Follow-Up Studies ,Forecasting - Abstract
It has been estimated that at least a third of the most common cancers are related to lifestyle and as such are preventable. Key modifiable lifestyle factors have been individually associated with cancer risk; however, less is known about the combined effects of these factors. This study generated a healthy lifestyle index score (HLIS) to investigate the joint effect of modifiable factors on the risk of overall cancers, alcohol-related cancers, tobacco-related cancers, obesity-related cancers, and reproductive-related cancers. The study included 391,608 men and women from the multinational European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. The HLIS was constructed from 5 factors assessed at baseline (diet, physical activity, smoking, alcohol consumption, and anthropometry) by assigning scores of 0 to 4 to categories of each factor, for which higher values indicate healthier behaviors. Hazard ratios (HR) were estimated by Cox proportional regression and population attributable fractions (PAFs) estimated from the adjusted models. There was a 5% lower risk (adjusted HR 0.952, 95% confidence interval (CI): 0.946, 0.958) of all cancers per point score of the index for men and 4% (adjusted HR 0.961, 95% CI: 0.956, 0.966) for women. The fourth versus the second category of the HLIS was associated with a 28% and 24% lower risk for men and women respectively across all cancers, 41%and 33%for alcohol-related, 49%and 46%for tobacco-related, 41% and 26% for obesity-related, and 21% for female reproductive cancers. Findings suggest simple behavior modifications could have a sizeable impact on cancer prevention, especially for men.
- Published
- 2016
60. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition
- Author
-
Aleksandrova, K., Bamia, C., Drogan, D., Lagiou, P., Trichopoulou, A., Jenab, M., Fedirko, V., Romieu, I., Bueno-de-Mesquita, H. B., Pischon, T., Tsilidis, K., Overvad, K., Tjonneland, A., Bouton-Ruault, M. C., Dossus, L., Racine, A., Kaaks, R., Kuhn, T., Tsironis, C., Papatesta, E. M., Saitakis, G., Palli, D., Panico, S., Grioni, S., Tumino, R., Vineis, P., Peeters, P. H., Weiderpass, E., Lukic, M., Braaten, T., Quiros, J. R., Lujan-Barroso, L., Sanchez, M. J., Chilarque, M. D., Ardanas, E., Dorronsoro, M., Nilsson, L. M., Sund, M., Wallstrom, P., Ohlsson, B., Bradbury, K. E., Khaw, K. T., Wareham, N., Stepien, M., Duarte-Salles, T., Assi, N., Gunter, M. J., Riboli, E., Boeing, H., and Trichopoulos, D.
- Subjects
SDG 3 - Good Health and Well-being - Published
- 2015
61. Insulin-like growth factor I and risk of breast cancer by age and hormone receptor status-A prospective study within the EPIC cohort
- Author
-
Kaaks R, Johnson T, Tikk K, Sookthai D, Tjønneland A, Roswall N, Overvad K, Clavel-Chapelon F, Mc, Boutron-Ruault, Dossus L, Rinaldi S, Romieu I, Boeing H, Schütze M, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Grioni S, Tumino R, Sacerdote C, Panico S, Buckland G, Argüelles M, Mj, Sánchez, Amiano P, Md, Chirlaque, Ardanaz E, Hb, Bueno-De-Mesquita, Ch, Gils, Ph, Peeters, Andersson A, Malin Sund, Weiderpass E, Torhild Gram I, Lund E, Kt, Khaw, Wareham N, Tj, Key, Rc, Travis, Ma, Merritt, Mj, Gunter, Riboli E, Lukanova A, Kaaks, R, Johnson, T, Tikk, K, Sookthai, D, Tj?nneland, A, Roswall, N, Overvad, K, Clavel Chapelon, F, Boutron Ruault, Mc, Dossus, L, Rinaldi, S, Romieu, I, Boeing, H, Sch?tze, M, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Grioni, S, Tumino, R, Sacerdote, C, Panico, Salvatore, Buckland, G, Arg?elles, M, S?nchez, Mj, Amiano, P, Chirlaque, Md, Ardanaz, E, Bueno de Mesquita, Hb, van Gils, Ch, Peeters, Ph, Andersson, A, Sund, M, Weiderpass, E, Torhild Gram, I, Lund, E, Khaw, Kt, Wareham, N, Key, Tj, Travis, Rc, Merritt, Ma, Gunter, Mj, Riboli, E, and Lukanova, A.
- Subjects
Adult ,Age Factors ,Estrogen Receptor alpha ,Breast Neoplasms ,Enzyme-Linked Immunosorbent Assay ,Middle Aged ,Prognosis ,Risk Factors ,Case-Control Studies ,Biomarkers, Tumor ,Humans ,Female ,Prospective Studies ,Insulin-Like Growth Factor I ,Menopause ,Receptors, Progesterone ,Aged ,Follow-Up Studies - Abstract
Experimental evidence shows cross-talk in mammary cells between estrogen, insulin-like growth factor I (IGF-I) and their respective receptors and possible synergistic effects of estrogen receptor (ER) activation and increased IGF-I signaling with regard to breast tumor development, and epidemiological evidence suggests that circulating IGF-I levels may be related more to the risk of ER-positive than ER-negative breast cancer. Using a case-control study nested within the prospective European EPIC cohort (938 breast cancer cases and 1,394 matched control subjects), we analyzed the relationships of prediagnostic serum IGF-I levels with the risk of estrogen and progesterone receptor-positive and -negative breast tumors. IGF-I levels were positively associated with the risk of ER+ breast tumors overall (pre- and postmenopausal women combined, odds ratio (OR)Q4-Q1 = 1.41 [95% confidence interval (CI) 1.01-1.98] for the highest vs. lowest quartile; OR = 1.17 [95% CI 1.04-1.33] per 1-standard deviation (SD) increase in IGF-I, ptrend = 0.01) and among women who were diagnosed with breast cancer at 50 years or older (ORQ3-Q1 = 1.38 [95% CI 1.01-1.89]; OR = 1.19 [95% CI 1.04-1.36] per 1-SD increase in IGF-I, ptrend = 0.01) but not with receptor-positive disease diagnosed at an earlier age. No statistically significant associations were observed for ER- breast tumors overall and by age at diagnosis. Tests for heterogeneity by receptor status of the tumor were not statistically significant, except for women diagnosed with breast cancer at 50 years or older (phet = 0.03 for ER+/PR+ vs. ER-/PR- disease). Our data add to a global body of evidence indicating that higher circulating IGF-I levels may increase risk specifically of receptor-positive, but not receptor-negative, breast cancer diagnosed at 50 years or older.
- Published
- 2013
62. Fish consumption and mortality in the European Prospective Investigation into Cancer and Nutrition cohort
- Author
-
Engeset, D. Braaten, T. Teucher, B. Kühn, T. Bueno-de-Mesquita, H.B. Leenders, M. Agudo, A. Bergmann, M.M. Valanou, E. Naska, A. Trichopoulou, A. Key, T.J. Crowe, F.L. Overvad, K. Sonestedt, E. Mattiello, A. Peeters, P.H. Wennberg, M. Jansson, J.H. Boutron-Ruault, M.-C. Dossus, L. Dartois, L. Li, K. Barricarte, A. Ward, H. Riboli, E. Agnoli, C. Huerta, J.M. Sánchez, M.-J. Tumino, R. Altzibar, J.M. Vineis, P. Masala, G. Ferrari, P. Muller, D.C. Johansson, M. Luisa Redondo, M. Tjønneland, A. Olsen, A. Olsen, K.S. Brustad, M. Skeie, G. Lund, E.
- Abstract
Fish is a source of important nutrients and may play a role in preventing heart diseases and other health outcomes. However, studies of overall mortality and cause-specific mortality related to fish consumption are inconclusive. We examined the rate of overall mortality, as well as mortality from ischaemic heart disease and cancer in relation to the intake of total fish, lean fish, and fatty fish in a large prospective cohort including ten European countries. More than 500,000 men and women completed a dietary questionnaire in 1992–1999 and were followed up for mortality until the end of 2010. 32,587 persons were reported dead since enrolment. Hazard ratios and their 99 % confidence interval were estimated using Cox proportional hazard regression models. Fish consumption was examined using quintiles based on reported consumption, using moderate fish consumption (third quintile) as reference, and as continuous variables, using increments of 10 g/day. All analyses were adjusted for possible confounders. No association was seen for fish consumption and overall or cause-specific mortality for both the categorical and the continuous analyses, but there seemed to be a U-shaped trend (p
- Published
- 2015
63. Risk of second primary malignancies in women with breast cancer: Results from the European prospective investigation into cancer and nutrition (EPIC)
- Author
-
Ricceri, F, Fasanelli, F, Giraudo, MT, Sieri, S, Tumino, R, Mattiello, A, Vagliano, L, Masala, G, Ramon Quiros, J, Travier, N, Sanchez, M-J, Larranaga, N, Chirlaque, M-D, Ardanaz, E, Tjonneland, A, Olsen, A, Overvad, K, Chang-Claude, J, Kaaks, R, Boeing, H, Clavel-Chapelon, FO, Kvaskoff, M, Dossus, L, Trichopoulou, A, Benetou, V, Adarakis, G, Bueno-de-Mesquita, HBA, Peeters, PH, Sund, M, Andersson, A, Borgquist, S, Butt, S, Weiderpass, E, Skeie, G, Khaw, K-T, Travis, RC, Rinaldi, S, Romieu, I, Gunter, M, Kadi, M, Riboli, E, Vineis, P, and Sacerdote, C
- Subjects
Adult ,Cancer Research ,Breast Neoplasms ,Body Mass Index ,tumour size ,REGISTRIES ,breast cancer ,Pregnancy ,Risk Factors ,Humans ,Neoplasm Invasiveness ,Oncology & Carcinogenesis ,second primary tumours ,Aalen-Johansen estimator ,Aged ,Proportional Hazards Models ,SURVIVORS ,Medicine(all) ,Science & Technology ,Age Factors ,Neoplasms, Second Primary ,Middle Aged ,TUMORS ,Oncology ,Female ,Menopause ,Life Sciences & Biomedicine ,1112 Oncology And Carcinogenesis ,RADIOTHERAPY ,Follow-Up Studies - Abstract
Women with a diagnosis of breast cancer are at increased risk of second primary cancers, and the identification of risk factors for the latter may have clinical implications. We have followed-up for 11 years 10,045 women with invasive breast cancer from a European cohort, and identified 492 second primary cancers, including 140 contralateral breast cancers. Expected and observed cases and Standardized Incidence Ratios (SIR) were estimated using Aalen-Johansen Markovian methods. Information on various risk factors was obtained from detailed questionnaires and anthropometric measurements. Cox proportional hazards regression models were used to estimate the role of risk factors. Women with breast cancer had a 30% excess risk for second malignancies (95% confidence interval - CI 18-42) after excluding contralateral breast cancers. Risk was particularly elevated for colorectal cancer (SIR, 1.71, 95% CI 1.43-2.00), lymphoma (SIR 1.80, 95% CI 1.31-2.40), melanoma (2.12; 1.63-2.70), endometrium (2.18; 1.75-2.70) and kidney cancers (2.40; 1.57-3.52). Risk of second malignancies was positively associated with age at first cancer, body mass index and smoking status, while it was inversely associated with education, post-menopausal status and a history of full-term pregnancy. We describe in a large cohort of women with breast cancer a 30% excess of second primaries. Among risk factors for breast cancer, a history of full-term pregnancy was inversely associated with the risk of second primary cancer. What's new? For the first time, researchers have used cohort data to show that people who survive breast cancer have a higher risk of developing another cancer later. By collecting data on 10,000 breast cancer patients over 11 years, these authors calculated a 30% boost in the patients' risk of developing a second primary malignancy, particularly colorectal cancer, lymphoma, melanoma, endometrial cancer, and kidney cancer. These findings, plus the data they collected on risk factors such as age, smoking, body mass index, and others, will help guide clinicians in screening procedures and follow up care for breast cancer patients.
- Published
- 2015
64. Association of CRP genetic variants with blood concentrations of C-reactive protein and colorectal cancer risk
- Author
-
Nimptsch, K. Aleksandrova, K. Boeing, H. Janke, J. Lee, Y.-A. Jenab, M. Bueno-De-Mesquita, H.B. Jansen, E.H.J.M. Tsilidis, K.K. Trichopoulou, A. Weiderpass, E. Wu, C. Overvad, K. Tjønneland, A. Boutron-Ruault, M.-C. Dossus, L. Racine, A. Kaaks, R. Canzian, F. Lagiou, P. Trichopoulos, D. Palli, D. Agnoli, C. Tumino, R. Vineis, P. Panico, S. Johansson, A. Van Guelpen, B. Khaw, K.-T. Wareham, N. Peeters, P.H. Quirós, J.R. García, A.V. Molina-Montes, E. Dorronsoro, M. Chirlaque, M.-D. Gurrea, A.B. Key, T.J. Duarte-Salles, T. Stepien, M. Gunter, M.J. Riboli, E. Pischon, T.
- Abstract
High blood concentrations of C-reactive protein (CRP) have been associated with elevated risk of colorectal cancer in several prospective studies including the European Prospective Investigation into Cancer and Nutrition (EPIC), but it is unknown whether these observations reflect a causal relationship. We aimed to investigate whether CRP genetic variants associated with lifelong higher CRP concentrations translate into higher colorectal cancer risk. We conducted a prospective nested case-control study within EPIC including 727 cases diagnosed between 1992 and 2003 and 727 matched controls selected according to an incidence-density sampling protocol. Baseline CRP concentrations were measured in plasma samples by a high sensitivity assay. Tagging single nucleotide polymorphisms (SNPs) in the CRP gene (rs1205, rs1800947, rs1130864, rs2808630, rs3093077) were identified via HapMap. The causal effect of CRP on colorectal cancer risk was examined in a Mendelian Randomization approach utilizing multiple CRP genetic variants as instrumental variables. The SNPs rs1205, rs1800947, rs1130864 and rs3093077 were significantly associated with CRP concentrations and were incorporated in a CRP allele score which was associated with 13% higher CRP concentrations per allele count (95% confidence interval 8-19%). Using the CRPscore as instrumental variable, genetically twofold higher CRP concentrations were associated with higher risk of colorectal cancer (odds ratio 1.74, 95% confidence interval 1.06-2.85). Similar observations were made using alternative definitions of instrumental variables. Our findings give support to the hypothesis that elevated circulating CRP may play a direct role in the etiology of colorectal cancer. © 2014 UICC.
- Published
- 2015
65. Diabetes and onset of natural menopause: results from the European Prospective Investigation into Cancer and Nutrition
- Author
-
Brand, J.S. Onland-Moret, N.C. Eijkemans, M.J.C. Tjønneland, A. Roswall, N. Overvad, K. Fagherazzi, G. Clavel-Chapelon, F. Dossus, L. Lukanova, A. Grote, V. Bergmann, M.M. Boeing, H. Trichopoulou, A. Tzivoglou, M. Trichopoulos, D. Grioni, S. Mattiello, A. Masala, G. Tumino, R. Vineis, P. Bueno-De-Mesquita, H.B. Weiderpass, E. Redondo, M.L. Sánchez, M.J. Huerta Castaño, J.M. Arriola, L. Ardanaz, E. Duell, E.J. Rolandsson, O. Franks, P.W. Butt, S. Nilsson, P. Khaw, K.T. Wareham, N. Travis, R. Romieu, I. Gunter, M.J. Riboli, E. Van Der Schouw, Y.T.
- Abstract
STUDY QUESTION: Do women who have diabetes before menopause have their menopause at an earlier age compared with women without diabetes? SUMMARY ANSWER: Although there was no overall association between diabetes and age at menopause, our study suggests that early-onset diabetes may accelerate menopause. WHAT IS KNOWN ALREADY: Today, more women of childbearing age are being diagnosed with diabetes, but little is known about the impact of diabetes on reproductive health. STUDY DESIGN, SIZE, DURATION: We investigated the impact of diabetes on age at natural menopause (ANM) in 258 898 women from the European Prospective Investigation into Cancer and Nutrition (EPIC), enrolled between 1992 and 2000. PARTICIPANTS/MATERIALS, SETTING, METHODS: Determinant and outcome information was obtained through questionnaires. Time-dependent Cox regression analyses were used to estimate the associations of diabetes and age at diabetes diagnosis with ANM, stratified by center and adjusted for age, smoking, reproductive and diabetes risk factors and with age from birth to menopause or censoring as the underlying time scale. MAIN RESULTS AND THE ROLE OF CHANCE: Overall, no association between diabetes and ANM was found (hazard ratio (HR) = 0.94; 95% confidence interval (CI) 0.89-1.01). However, women with diabetes before the age of 20 years had an earlier menopause (10-20 years: HR = 1.43; 95% CI 1.02-2.01
- Published
- 2015
66. Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort
- Author
-
Ose, J. Fortner, R. T. Schock, H. Peeters, P. H. and Onland-Moret, N. C. Bueno-de-Mesquita, H. B. Weiderpass, E. and Gram, I. T. Overvad, K. Tjonneland, A. Dossus, L. and Fournier, A. Baglietto, L. Trichopoulou, A. Benetou, V. and Trichopoulos, D. Boeing, H. Masala, G. Krogh, V. and Matiello, A. Tumino, R. Popovic, M. Obon-Santacana, M. and Larranaga, N. Ardanaz, E. Sanchez, M-J Menendez, V. and Chirlaque, M-D Travis, R. C. Khaw, K-T Braendstedt, J. and Idahl, A. Lundin, E. Rinaldi, S. Kuhn, E. Romieu, I. and Gunter, M. J. Merritt, M. A. Riboli, E. Kaaks, R.
- Subjects
endocrine system diseases ,female genital diseases and pregnancy complications - Abstract
Background: Prospective studies on insulin-like growth factor I (IGF-I) and epithelial ovarian cancer (EOC) risk are inconclusive. Data suggest risk associations vary by tumour characteristics. Methods: We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) to evaluate IGF-I concentrations and EOC risk by tumour characteristics (n = 565 cases). Multivariable conditional logistic regression models were used to estimate associations. Results: We observed no association between IGF-I and EOC overall or by tumour characteristics. Conclusions: In the largest prospective study to date was no association between IGF-I and EOC risk. Pre-diagnostic serum IGF-I concentrations may not influence EOC risk.
- Published
- 2015
67. Diabetes mellitus, glycatedhaemoglobin and C-peptide levels in relation to pancreatic cancer risk: a studywithin the European Prospective Investigation into Cancer and Nutrition (EPIC)cohort
- Author
-
Grote VA, Rohrmann S, Nieters A, Dossus L, Tjønneland A, Halkjær J, Overvad K, Fagherazzi G, Boutron Ruault MC, Morois S, Teucher B, Becker S, Sluik D, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Pala V, Tumino R, Vineis P, Rodríguez L, Duell EJ, Molina Montes E, Dorronsoro M, Huerta JM, Ardanaz E, Jeurnink SM, Beulens JW, Peeters PH, Sund M, Ye W, Lindkvist B, Johansen D, Khaw KT, Wareham N, Allen N, Crowe F, Jenab M, Romieu I, Michaud DS, Riboli E, Romaguera D, Bueno de Mesquita HB, Kaaks R., PANICO, SALVATORE, Grote, Va, Rohrmann, S, Nieters, A, Dossus, L, Tjønneland, A, Halkjær, J, Overvad, K, Fagherazzi, G, Boutron Ruault, Mc, Morois, S, Teucher, B, Becker, S, Sluik, D, Boeing, H, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Pala, V, Tumino, R, Vineis, P, Panico, Salvatore, Rodríguez, L, Duell, Ej, Molina Montes, E, Dorronsoro, M, Huerta, Jm, Ardanaz, E, Jeurnink, Sm, Beulens, Jw, Peeters, Ph, Sund, M, Ye, W, Lindkvist, B, Johansen, D, Khaw, Kt, Wareham, N, Allen, N, Crowe, F, Jenab, M, Romieu, I, Michaud, D, Riboli, E, Romaguera, D, Bueno de Mesquita, Hb, and Kaaks, R.
- Published
- 2011
68. Postmenopausalserum sex steroids and risk of hormone receptor-positive and -negative breastcancer: a nested case-control study
- Author
-
James RE, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjønneland A, Olsen A, Overvad K, Mesrine S, Engel P, Clavel Chapelon F, Chang Claude J, Vrieling A, Boeing H, Schütze M, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Krogh V, Tumino R, Sacerdote C, Rodríguez L, Buckland G, Sánchez MJ, Amiano P, Ardanaz E, Bueno de Mesquita B, Ros MM, van Gils CH, Peeters PH, Khaw KT, Wareham N, Key TJ, Allen NE, Romieu I, Siddiq A, Cox D, Riboli E, Kaaks R., PANICO, SALVATORE, James, Re, Lukanova, A, Dossus, L, Becker, S, Rinaldi, S, Tjønneland, A, Olsen, A, Overvad, K, Mesrine, S, Engel, P, Clavel Chapelon, F, Chang Claude, J, Vrieling, A, Boeing, H, Schütze, M, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Krogh, V, Panico, Salvatore, Tumino, R, Sacerdote, C, Rodríguez, L, Buckland, G, Sánchez, Mj, Amiano, P, Ardanaz, E, Bueno de Mesquita, B, Ros, Mm, van Gils, Ch, Peeters, Ph, Khaw, Kt, Wareham, N, Key, Tj, Allen, Ne, Romieu, I, Siddiq, A, Cox, D, Riboli, E, and Kaaks, R.
- Published
- 2011
69. Healthy lifestyle and risk of breast cancer among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition cohort study
- Author
-
Mckenzie, F, Ferrari, P, Freisling, H, Chajès, V, Rinaldi, S, de Batlle, J, Dahm, CC, Overvad, K, Baglietto, L, Dartois, L, Dossus, L, Lagiou, P, Trichopoulos, D, Trichopoulou, A, Krogh, V, Panico, S, Tumino, R, Rosso, S, Bueno-de-Mesquita, HB, May, A, Peeters, PH, Weiderpass, E, Buckland, G, Sanchez, M-J, Navarro, C, Ardanaz, E, Andersson, A, Sund, M, Ericson, U, Wirfält, E, Key, TJ, Travis, RC, Gunter, M, Riboli, E, Vergnaud, A-C, Romieu, I, Mckenzie, Fiona, Ferrari, Pietro, Freisling, Heinz, Chajès, Veronique, Rinaldi, Sabina, de Batlle, Jordi, Dahm, Christina C, Overvad, Kim, Baglietto, Laura, Dartois, Laureen, Dossus, Laure, Lagiou, Pagona, Trichopoulos, Dimitrio, Trichopoulou, Antonia, Krogh, Vittorio, Panico, Salvatore, Tumino, Rosario, Rosso, Stefano, Bueno de Mesquita, H. B. A, May, Anne, Peeters, Petra H, Weiderpass, Elisabete, Buckland, Genevieve, Sanchez, Maria Jose, Navarro, Carmen, Ardanaz, Eva, Andersson, Anne, Sund, Malin, Ericson, Ulrika, Wirfält, Elisabet, Key, Tim J, Travis, Ruth C, Gunter, Marc, Riboli, Elio, Vergnaud, Anne Claire, and Romieu, Isabelle
- Subjects
b reast cancer ,Europe ,healthy index ,lifestyle ,prospective studies ,Medicine (all) ,Oncology ,Cancer Research ,MEXICAN WOMEN ,DIETARY FIBER ,Alcohol Drinking ,Health Status ,prospective studie ,European Continental Ancestry Group ,Breast Neoplasms ,White People ,Health Statu ,breast cancer ,ADHERENCE ,Risk Factors ,Journal Article ,Humans ,CORONARY-HEART-DISEASE ,Prospective Studies ,Oncology & Carcinogenesis ,Exercise ,Life Style ,METAANALYSIS ,Science & Technology ,Anthropometry ,Risk Factor ,Research Support, Non-U.S. Gov't ,ASSOCIATION ,Middle Aged ,PREVENTION ,Diet ,Postmenopause ,GLYCEMIC INDEX ,Women's Health ,Female ,CIGARETTE-SMOKING ,FATTY-ACIDS ,Life Sciences & Biomedicine ,Risk Reduction Behavior ,1112 Oncology And Carcinogenesis ,Breast Neoplasm ,Human - Abstract
Breast cancer is the most common cancer among women and prevention strategies are needed to reduce incidence worldwide. A healthy lifestyle index score (HLIS) was generated to investigate the joint effect of modifiable lifestyle factors on postmenopausal breast cancer risk. The study included 242,918 postmenopausal women from the multinational European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, with detailed information on diet and lifestyle assessed at baseline. The HLIS was constructed from five factors (diet, physical activity, smoking, alcohol consumption and anthropometry) by assigning scores of 0-4 to categories of each component, for which higher values indicate healthier behaviours. Hazard ratios (HR) were estimated by Cox proportional regression models. During 10.9 years of median follow-up, 7,756 incident breast cancer cases were identified. There was a 3% lower risk of breast cancer per point increase of the HLIS. Breast cancer risk was inversely associated with a high HLIS when fourth versus second (reference) categories were compared [adjusted HR=0.74; 95% confidence interval (CI): 0.66-0.83]. The fourth versus the second category of the HLIS was associated with a lower risk for hormone receptor double positive (adjusted HR=0.81, 95% CI: 0.67-0.98) and hormone receptor double negative breast cancer (adjusted HR=0.60, 95% CI: 0.40-0.90). Findings suggest having a high score on an index of combined healthy behaviours reduces the risk of developing breast cancer among postmenopausal women. Programmes which engage women in long term health behaviours should be supported. What's new? How much does behavior really affect cancer risk? These authors set out to measure just that. First, they created a Healthy Lifestyle Index, which quantified five modifiable behaviors, such as smoking and physical activity. Then, using data from the European Prospective Investigation into Cancer and Nutrition (EPIC), they assigned each participant a score between 0 and 4 on each of the behaviors. It turned out that with each point added to a person's Healthy Lifestyle Index score, breast cancer risk fell by 3%, suggesting that public programs to help women maintain these behaviors could be worthwhile for cancer prevention.
- Published
- 2014
70. Insulin-like growth factor i and risk of breast cancer by age and hormone receptor status - A prospective study within the EPIC cohort
- Author
-
Kaaks, R, Johnson, T, Tikk, K, Sookthai, D, Tjønneland, A, Roswall, N, Overvad, K, Clavel-Chapelon, F, Boutron-Ruault, M-C, Dossus, L, Rinaldi, S, Romieu, I, Boeing, H, Schütze, M, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Grioni, S, Tumino, R, Sacerdote, C, Panico, S, Buckland, G, Argüelles, M, Sánchez, M-J, Amiano, P, Chirlaque, M-D, Ardanaz, E, Bueno-De-Mesquita, HB, Van Gils, CH, Peeters, PH, Andersson, A, Sund, M, Weiderpass, E, Gram, IT, Lund, E, Khaw, K-T, Wareham, N, Key, TJ, Travis, RC, Merritt, MA, Gunter, MJ, Riboli, E, and Lukanova, A
- Abstract
Experimental evidence shows cross-talk in mammary cells between estrogen, insulin-like growth factor I (IGF-I) and their respective receptors and possible synergistic effects of estrogen receptor (ER) activation and increased IGF-I signaling with regard to breast tumor development, and epidemiological evidence suggests that circulating IGF-I levels may be related more to the risk of ER-positive than ER-negative breast cancer. Using a case-control study nested within the prospective European EPIC cohort (938 breast cancer cases and 1,394 matched control subjects), we analyzed the relationships of prediagnostic serum IGF-I levels with the risk of estrogen and progesterone receptor-positive and -negative breast tumors. IGF-I levels were positively associated with the risk of ER+ breast tumors overall (pre- and postmenopausal women combined, odds ratio (OR)Q4-Q1 = 1.41 [95% confidence interval (CI) 1.01-1.98] for the highest vs. lowest quartile; OR = 1.17 [95% CI 1.04-1.33] per 1-standard deviation (SD) increase in IGF-I, ptrend = 0.01) and among women who were diagnosed with breast cancer at 50 years or older (ORQ3-Q1 = 1.38 [95% CI 1.01-1.89]; OR = 1.19 [95% CI 1.04-1.36] per 1-SD increase in IGF-I, ptrend = 0.01) but not with receptor-positive disease diagnosed at an earlier age. No statistically significant associations were observed for ER- breast tumors overall and by age at diagnosis. Tests for heterogeneity by receptor status of the tumor were not statistically significant, except for women diagnosed with breast cancer at 50 years or older (phet = 0.03 for ER+/PR+ vs. ER-/PR- disease). Our data add to a global body of evidence indicating that higher circulating IGF-I levels may increase risk specifically of receptor-positive, but not receptor-negative, breast cancer diagnosed at 50 years or older. What's new Both estrogen and insulin-like growth factor (IGF-I) promote breast cancer formation, and evidence suggests the two may work together. Some breast tumors express estrogen receptor, others don't. Does the presence of estrogen receptor allow IGF-I to stimulate tumor formation To address this question, the authors compared women's IGF-I levels before diagnosis with their risk of developing breast cancer, with or without estrogen receptor. They found a direct relationship between IGF levels and risk of ER-positive breast tumors diagnosed after age 50. They found no association with ER-positive tumors diagnosed at an earlier age, nor with ER-negative tumors. © 2013 UICC.
- Published
- 2014
71. Active and passive cigarette smoking and breast cancer risk: results from the EPIC cohort
- Author
-
Dossus, L., Boutron-Ruault, M.C., Kaaks, R., Gram, I.T., Vilier, A., Fervers, B., Manjer, J., Tjonneland, A., Olsen, A., Overvad, K., Chang-Claude, J., Boeing, H., Steffen, A., Trichopoulou, A., Lagiou, P., Sarantopoulou, M., Palli, D., Berrino, F., Tumino, R., Vineis, P., Mattiello, A., Bueno-de-Mesquita, H.B., and van Duijnhoven, F.J.B.
- Subjects
Nutrition and Disease ,association ,reanalysis ,postmenopausal women ,never smokers ,carcinogens ,california teachers ,environmental tobacco-smoke ,exposure ,Voeding en Ziekte ,1st childbirth ,VLAG ,metaanalysis - Abstract
Recent cohort studies suggest that increased breast cancer risks were associated with longer smoking duration, higher pack-years and a dose-response relationship with increasing pack-years of smoking between menarche and first full-term pregnancy (FFTP). Studies with comprehensive quantitative life-time measures of passive smoking suggest an association between passive smoking dose and breast cancer risk. We conducted a study within the European Prospective Investigation into Cancer and Nutrition to examine the association between passive and active smoking and risk of invasive breast cancer and possible effect modification by known breast cancer risk factors. Among the 322,988 women eligible for the study, 9,822 developed breast cancer (183,608 women with passive smoking information including 6,264 cases). When compared to women who never smoked and were not being exposed to passive smoking at home or work at the time of study registration, current, former and currently exposed passive smokers were at increased risk of breast cancer (hazard ratios (HR) [95% confidence interval (CI)] 1.16 [1.05–1.28], 1.14 [1.04–1.25] and 1.10 [1.01–1.20], respectively). Analyses exploring associations in different periods of life showed the most important increase in risk with pack-years from menarche to FFTP (1.73 [1.29–2.32] for every increase of 20 pack-years) while pack-years smoked after menopause were associated with a significant decrease in breast cancer risk (HR = 0.53, 95% CI: 0.34–0.82 for every increase of 20 pack-years). Our results provide an important replication, in the largest cohort to date, that smoking (passively or actively) increases breast cancer risk and that smoking between menarche and FFTP is particularly deleterious.
- Published
- 2014
72. Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort
- Author
-
Tikk, K. Sookthai, D. Johnson, T. Rinaldi, S. Romieu, I. and Tjonneland, A. Olsen, A. Overvad, K. Clavel-Chapelon, F. and Baglietto, L. Boeing, H. Trichopoulou, A. Lagiou, P. and Trichopoulos, D. Palli, D. Pala, V. Tumino, R. Rosso, S. and Panico, S. Agudo, A. Menendez, V. Sanchez, M. -J. and Amiano, P. Huerta Castano, J. M. Ardanaz, E. and Bueno-de-Mesquita, H. B. Monninkhof, E. Onland-Moret, C. and Andersson, A. Sund, M. Weiderpass, E. Khaw, K. -T. Key, T. J. Travis, R. C. Gunter, M. J. Riboli, E. Dossus, L. and Kaaks, R.
- Abstract
Experimental and epidemiological evidence suggests that prolactin might play a role in the etiology of breast cancer. We analyzed the relationship of prediagnostic circulating prolactin levels with the risk of breast cancer by menopausal status, use of postmenopausal hormone replacement therapy (HRT) at blood donation, and by estrogen and progesterone receptor status of the breast tumors. Conditional logistic regression was used to analyze the data from a case-control study nested within the prospective European EPIC cohort, including 2250 invasive breast cancer and their matched control subjects. Statistically significant heterogeneity in the association of prolactin levels with breast cancer risk between women who were either pre- or postmenopausal at the time of blood donation was observed (P-het = 0.04). Higher serum levels of prolactin were associated with significant increase in the risk of breast cancer among postmenopausal women [odds ratio (OR)(Q4-Q1) = 1.29 (95% confidence interval, CI, 1.05-1.58), P-trend = 0.09]; however, this increase in risk seemed to be confined to women who used postmenopausal HRT at blood donation [ORQ4-Q1 = 1.45 (95% CI 1.08-1.95), P-trend = 0.01], whereas no statistically significant association was found for the non-users of HRT [ORQ4-Q1 = 1.11 (95%CI 0.83-1.49), P-trend = 0.80] (P-het = 0.08). Among premenopausal women, a statistically non-significant inverse association was observed [ORQ4-Q1 = 0.70 (95% CI 0.48-1.03), P-trend = 0.16]. There was no heterogeneity in the prolactin-breast cancer association by hormone receptor status of the tumor. Our study indicates that higher circulating levels of prolactin among the postmenopausal HRT users at baseline may be associated with increased breast cancer risk.
- Published
- 2014
73. Dietary Intakes and Risk of Lymphoid and Myeloid Leukemia in the European Prospective Investigation into Cancer and Nutrition (EPIC)
- Author
-
Saberi Hosnijeh, F., Peeters, P.H.M., Romieu, I., Kelly, R., Riboli, E., Olsen, A., Tjonneland, A., Fagherazzi, g., Clavel Chapelon, F., Dossus, L., Nieters, A., Teucher, B., Trichopoulo, A., Naska, A., Valanou, E., Mattiello, A., Sieri, S., Parr, C.L., Engeset, D., Bueno de Mesquita, H.B., Ros, M.M., Travis, R.C., Key, T.J., Vineis, P., Vermeulen, R.C.H., Risk Assessment of Toxic and Immunomodulatory Agents, IRAS RATIA-SIB, LS IRAS EEPI GRA (Gezh.risico-analyse), and Dep IRAS
- Subjects
hemic and lymphatic diseases ,Scientific - Abstract
The etiology of leukemias cannot entirely be explained by known risk factors, including ionizing radiation, benzene exposure, and infection with human T cell leukemia virus. A number of studies suggested that diet influences the risk of adult leukemias. However, results have been largely inconsistent. We examined the potential association between dietary factors and risk of leukemias among participants of the European Prospective Investigation into Cancer and Nutrition study. Among the 477,325 participants with mean follow-up of 11.34 yr (SD = 2.47), 773 leukemias (373 and 342 cases of lymphoid and myeloid leukemia, respectively) were identified. Diet over the previous 12 mo was assessed at baseline using a validated country-specific dietary questionnaire. Cox proportional hazards regression was used to explore the association between dietary factors that have previously been associated with leukemia risk, including red and processed meat, poultry, offal, fish, dairy products, vegetables, fruits, and seeds/nuts, and risk of both lymphoid and myeloid leukemias. No significant associations were observed between dietary measures and total, lymphoid, and myeloid leukemias. Additional subtype analyses showed no dietary association with risk of major subtypes of leukemias. In summary, this study did not support a possible link between selected dietary factors and risk of leukemias.
- Published
- 2014
74. Dietary intake of acrylamide and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort
- Author
-
Obon-Santacana, M. Kaaks, R. Slimani, N. Lujan-Barroso, L. and Freisling, H. Ferrari, P. Dossus, L. Chabbert-Buffet, N. and Baglietto, L. Fortner, R. T. Boeing, H. Tjonneland, A. and Olsen, A. Overvad, K. Menendez, V. Molina-Montes, E. and Larranaga, N. Chirlaque, M-D Ardanaz, E. Khaw, K-T and Wareham, N. Travis, R. C. Lu, Y. Merritt, M. A. and Trichopoulou, A. Benetou, V. Trichopoulos, D. Saieva, C. and Sieri, S. Tumino, R. Sacerdote, C. Galasso, R. and Bueno-de-Mesquita, H. B. Wirfalt, E. Ericson, U. Idahl, A. and Ohlson, N. Skeie, G. Gram, I. T. Weiderpass, E. and Onland-Moret, N. C. Riboli, E. Duell, E. J.
- Abstract
Background: Three prospective studies have evaluated the association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent results. The objective of this study was to evaluate the association between acrylamide intake and EC risk: for overall EC, for type-I EC, and in never smokers and never users of oral contraceptives (OCs). Smoking is a source of acrylamide, and OC use is a protective factor for EC risk. Methods: Cox regression was used to estimate hazard ratios (HRs) for the association between acrylamide intake and EC risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Acrylamide intake was estimated from the EU acrylamide monitoring database, which was matched with EPIC questionnaire-based food consumption data. Acrylamide intake was energy adjusted using the residual method. Results: No associations were observed between acrylamide intake and overall EC (n = 1382) or type-I EC risk (n = 627). We observed increasing relative risks for type-I EC with increasing acrylamide intake among women who both never smoked and were non-users of OCs (HRQ5vsQ1: 1.97, 95% CI: 1.08-3.62; likelihood ratio test (LRT) P-value: 0.01, n = 203). Conclusions: Dietary intake of acrylamide was not associated with overall or type-I EC risk; however, positive associations with type I were observed in women who were both non-users of OCs and never smokers.
- Published
- 2014
75. Physical activity, sex steroid, and growth factor concentrations in pre- and post-menopausal women: a cross-sectional study within the EPIC cohort
- Author
-
Rinaldi, S. Kaaks, R. Friedenreich, C. M. Key, T. J. and Travis, R. Biessy, C. Slimani, N. Overvad, K. and Ostergaard, J. N. Tjonneland, A. Olsen, A. Mesrine, S. and Fournier, A. Dossus, L. Lukanova, A. Johnson, T. Boeing, H. Vigl, M. Trichopoulou, A. Benetou, V. Trichopoulos, D. Masala, G. Krogh, V. Tumino, R. Ricceri, F. and Panico, S. Bueno-de-Mesquita, H. B. Monninkhof, E. M. May, A. M. Weiderpass, E. Quiros, J. R. Travier, N. and Molina-Montes, E. Amiano, P. Huerta, J. M. Ardanaz, E. and Sund, M. Johansson, M. Khaw, K. T. Wareham, N. Scalbert, A. Gunter, M. J. Riboli, E. Romieu, I.
- Abstract
Increased physical activity (PA) is associated with a reduced risk of several cancers. PA may reduce cancer risk by changing endogenous hormones levels, but relatively little research has focused on this topic. The purpose of this study was to elucidate the relation between PA and endogenous hormone concentrations. A cross-sectional analysis of 798 pre- and 1,360 post-menopausal women included as controls in case-control studies on endogenous hormones (steroids, progesterone, sex-hormone-binding globulin (SHBG), and growth factors) levels, and cancer risk nested within European Prospective Investigation into Cancer and Nutrition cohort was performed. Multivariate regression analyses were performed to compare geometric mean levels of hormones and SHBG by categories of PA. In pre-menopausal women, active women had 19 % significantly lower concentrations of androstenedione, 14 % lower testosterone, and 20 % lower free testosterone than inactive women, while no differences were observed for estrogens, progesterone, SHBG, and growth factors. In post-menopausal women, active women had 18 % significantly lower estradiol and 20 % lower free estradiol concentrations than inactive women, while no differences were observed for the other hormones and SHBG. More vigorous forms of physical activity were associated with higher insulin-like growth factor-I concentrations. Adjustment for body mass index did not alter the associations. Overall, the percentage of variance in hormone concentrations explained by PA levels was < 2 %. Our results support the hypothesis of an influence, although small in magnitude, of PA on sex hormone levels in blood, independent of body size.
- Published
- 2014
76. Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women
- Author
-
GRAM IT, NORAT T, RINALDI S, DOSSUS L, LUKANOVA A, TEHARD B, CLAVEL CHAPELON, F, VAN GILS CH, VAN NOORD PA, PEETERS PH, BUENO DE MESQUITA HB, NAGEL G, LINSEISEN J, LAHMANN PH, BOEING H, PALLI D, SACERDOTE C, TUMINO R, SIERI S, DORRONSORO M, QUIROS JR, NAVARRO CA, BARRICARTE A, TORMO MJ, GONZALEZ, CA, OVERVAD K, PAASKE JOHNSEN S, OLSEN A, TJONNELAND A, TRAVIS R, ALLEN N, BINGHAM S, KHAW KT, STATTIN P, TRICHOPOULOU A, KALAPOTHAKI V, PSALTOPOULOU T, CASAGRANDE C, RIBOLI E, KAAKS R., PANICO, SALVATORE, Gram, It, Norat, T, Rinaldi, S, Dossus, L, Lukanova, A, Tehard, B, Clavel, Chapelon, F, VAN GILS, Ch, VAN NOORD, Pa, Peeters, Ph, BUENO DE MESQUITA, Hb, Nagel, G, Linseisen, J, Lahmann, Ph, Boeing, H, Palli, D, Sacerdote, C, Panico, Salvatore, Tumino, R, Sieri, S, Dorronsoro, M, Quiros, Jr, Navarro, Ca, Barricarte, A, Tormo, Mj, Gonzalez, Ca, Overvad, K, PAASKE JOHNSEN, S, Olsen, A, Tjonneland, A, Travis, R, Allen, N, Bingham, S, Khaw, Kt, Stattin, P, Trichopoulou, A, Kalapothaki, V, Psaltopoulou, T, Casagrande, C, Riboli, E, and Kaaks, R.
- Published
- 2006
77. Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - results from the EPIC cohort
- Author
-
Kaaks R, Tikk K, Sookthai D, Schock H, Johnson T, Tjønneland A, Olsen A, Overvad K, Clavel-Chapelon F, Dossus L, Baglietto L, Rinaldi S, Chajes V, Romieu I, Boeing H, Schütze M, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Sieri S, Tumino R, Ricceri F, Mattiello A, Buckland G, Ramón Quirós J, Mj, Sánchez, Amiano P, Md, Chirlaque, Barricarte A, Bas Bueno-de-Mesquita H, Ch, Gils, Ph, Peeters, Andersson A, Malin Sund, Weiderpass E, Kt, Khaw, Wareham N, Tj, Key, Rc, Travis, Ma, Merritt, Mj, Gunter, Riboli E, and Lukanova A
- Subjects
Adult ,Male ,Risk ,breast cancer ,EPIC ,estrogen receptor ,prospective cohort ,sex hormones ,Breast Neoplasms ,Case-Control Studies ,Cohort Studies ,Estradiol ,Female ,Gonadal Steroid Hormones ,Humans ,Middle Aged ,Premenopause ,Progesterone ,Prospective Studies ,Receptor, ErbB-2 ,Receptors, Estrogen ,Receptors, Progesterone ,Sex Hormone-Binding Globulin ,Testosterone ,Medicine (all) ,Oncology ,Cancer Research ,ErbB-2 ,Receptors ,Estrogen ,Receptor - Abstract
Results from prospective studies on premenopausal serum hormone levels in relation to breast cancer risk have been inconclusive, especially with regard to tumor subtypes. Using a case-control study nested within the prospective European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (801 breast cancer cases and 1,132 matched control subjects), we analyzed the relationships of prediagnostic serum estradiol, free estradiol, progesterone, testosterone, free testosterone and sex hormone-binding globulin (SHBG) levels with the risk of breast cancer by estrogen and progesterone receptor-positive and -negative breast tumors and by age at diagnoses. Higher prediagnostic serum levels of testosterone and free testosterone were associated with an increased overall risk of breast cancer [ORQ4-Q1 = 1.56 (95% CI 1.15-2.13), ptrend = 0.02 for testosterone and ORQ4-Q1 = 1.33 (95% CI 0.99-1.79), ptrend = 0.04 for free testosterone], but no significant risk association was observed for estradiol, free estradiol, progesterone and SHBG. Tests for heterogeneity between receptor-positive and -negative tumors were not significant. When analysis were stratified by age at tumor diagnosis, the odds ratios observed for estradiol were stronger and borderline significant for breast cancer diagnosed at age less than 50 [ORQ4-Q1 = 1.32 (95% CI 0.87-2.01), ptrend = 0.05] compared to breast cancer diagnosed at age 50 or above [ORQ4-Q1 = 0.94 (95% CI 0.60-1.47), ptrend = 0.34, phet = 0.04]. In conclusion, our data indicate that higher premenopausal circulating testosterone levels are associated with an increased risk of developing breast cancer, but do not show a significant association of estradiol or progesterone with breast cancer risk, overall, by menstrual cycle phase or by tumor receptor status, although a possible risk increase with higher estradiol levels for tumors diagnosed before age 50 was seen.
- Published
- 2013
78. Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study
- Author
-
Ritte, R, Lukanova, A, Tjønneland, A, Olsen, A, Overvad, K, Mesrine, S, Fagherazzi, G, Dossus, L, Teucher, B, Steindorf, K, Boeing, H, Aleksandrova, K, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Palli, D, Grioni, S, Mattiello, A, Tumino, R, Sacerdote, C, Quirõs, JR, Buckland, G, Molina-Montes, E, Chirlaque, MD, Ardanaz, E, Amiano, P, Bueno-De-Mesquita, B, Van Duijnhoven, F, Van Gils, CH, Peeters, PH, Wareham, N, Khaw, KT, Key, TJ, Travis, RC, Krum-Hansen, S, Gram, IT, Lund, E, Sund, M, Andersson, A, Romieu, I, Rinaldi, S, McCormack, V, Riboli, E, and Kaaks, R
- Subjects
Cancer Research ,Nutrition and Disease ,population ,Physiology ,exposures ,Risk Factors ,Voeding en Ziekte ,Prospective Studies ,Prospective cohort study ,estrogen-receptor ,education.field_of_study ,Age Factors ,Middle Aged ,Prognosis ,European Prospective Investigation into Cancer and Nutrition ,Europe ,Receptors, Estrogen ,Oncology ,Cohort ,Menarche ,Female ,Receptors, Progesterone ,associations ,Adult ,medicine.medical_specialty ,body-size ,growth ,Population ,Breast Neoplasms ,Breast cancer ,Biomarkers, Tumor ,medicine ,Humans ,Risk factor ,education ,VLAG ,childhood ,Gynecology ,Leg ,leg length ,business.industry ,Proportional hazards model ,Estrogens ,medicine.disease ,Body Height ,adolescence ,participants ,business ,Follow-Up Studies - Abstract
Associations of breast cancer overall with indicators of exposures during puberty are reasonably well characterized; however, uncertainty remains regarding the associations of height, leg length, sitting height and menarcheal age with hormone receptor-defined malignancies. Within the European Prospective Investigation into Cancer and Nutrition cohort, Cox proportional hazards models were used to describe the relationships of adult height, leg length and sitting height and age at menarche with risk of estrogen and progesterone receptor negative (ER-PR-) (n = 990) and ER+PR+ (n = 3,524) breast tumors. Height as a single risk factor was compared to a model combining leg length and sitting height. The possible interactions of height, leg length and sitting height with menarche were also analyzed. Risk of both ER-PR- and ER+PR+ malignancies was positively associated with standing height, leg length and sitting height and inversely associated with increasing age at menarche. For ER+PR+ disease, sitting height (hazard ratios: 1.14[95% confidence interval: 1.08-1.20]) had a stronger risk association than leg length (1.05[1.00-1.11]). In comparison, for ER-PR- disease, no distinct differences were observed between leg length and sitting height. Women who were tall and had an early menarche (≤13 years) showed an almost twofold increase in risk of ER+PR+ tumors but no such increase in risk was observed for ER-PR- disease. Indicators of exposures during rapid growth periods were associated with risks of both HR-defined breast cancers. Exposures during childhood promoting faster development may establish risk associations for both HR-positive and -negative malignancies. The stronger associations of the components of height with ER+PR+ tumors among older women suggest possible hormonal links that could be specific for postmenopausal women. What's new? Adult height and early age at menarche are established risk factors for breast cancer. In this study, the authors examined these factors in relation to the hormone-receptor status of breast tumors, with height divided into leg length vs. sitting height. They found that women who were tall and had an early menarche (≤13 years) had almost double the risk of developing estrogen/progesterone-positive (ER+PR+) tumors. Leg length and early menarche were also associated with increased risk for receptor-negative (ER-PR-) tumors. In addition, the data suggest possible hormonal links that could be specific for postmenopausal women. Copyright © 2012 UICC.
- Published
- 2013
79. Plasma 25(OH)vitamin D and the risk of breast cancer in the european prospective investigation into cancer and nutrition (EPIC): A nested case-control study
- Author
-
Kühn, T., Kaaks, R., Becker, S., Eomois, P.P., Clavel-Chapelon, F., Kvaskoff, M., Dossus, L., and van Duijnhoven, F.J.B.
- Subjects
calcium ,d-binding protein ,serum-levels ,Nutrition and Disease ,prevention ,Voeding en Ziekte ,association ,postmenopausal women ,nurses health ,french e3n cohort ,circulating vitamin-d ,time ,VLAG - Abstract
Experimental evidence suggests that vitamin D might play a role in the development of breast cancer. Although the results of case–control studies indicate that circulating 25-hydroxyvitamin D [25(OH)D] is inversely associated with the risk of breast cancer, the results of prospective studies are inconsistent. A case–control study embedded in the European Prospective Investigation into Cancer and Nutrition (EPIC) was carried out comprising 1,391 incident breast cancer cases and 1,391 controls. Multivariable conditional logistic regression models did not reveal a significant overall association between season-standardized 25(OH)D levels and the risk of breast cancer (ORQ4–Q1 [95% CI]: 1.07 [0.85–1.36], ptrend = 0.67). Moreover, 25(OH)D levels were not related to the risks of estrogen receptor positive tumors (ORQ4–Q1 [95% CI]: 0.97 [0.67–1.38], ptrend = 0.90) and estrogen receptor negative tumors (ORQ4–Q1 [95% CI]: 0.97 [0.66–1.42], ptrend = 0.98). In hormone replacement therapy (HRT) users, 25(OH)D was significantly inversely associated with incident breast cancer (ORlog2 [95% CI]: 0.62 [0.42–0.90], p = 0.01), whereas no significant association was found in HRT nonusers (ORlog2 [95% CI]: 1.14 [0.80–1.62], p = 0.48). Further, a nonsignificant inverse association was found in women with body mass indices (BMI)
- Published
- 2013
80. Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: A nested case-control study
- Author
-
Kühn, T, Kaaks, R, Becker, S, Eomois, P-P, Clavel-Chapelon, F, Kvaskoff, M, Dossus, L, Tjønneland, A, Olsen, A, Overvad, K, Chang-Claude, J, Lukanova, A, Buijsse, B, Boeing, H, Trichopoulou, A, Lagiou, P, Bamia, C, Masala, G, Krogh, V, Sacerdote, C, Tumino, R, Mattiello, A, Buckland, G, Sánchez, M-J, Menéndez, V, Chirlaque, M-D, Barricarte, A, Bueno-De-Mesquita, HB, Van Duijnhoven, FJB, Van Gils, CH, Bakker, MF, Weiderpass, E, Skeie, G, Brustad, M, Andersson, A, Sund, M, Wareham, N, Khaw, KT, Travis, RC, Schmidt, JA, Rinaldi, S, Romieu, I, Gallo, V, Murphy, N, Riboli, E, and Linseisen, J
- Subjects
Hormone Replacement Therapy ,Nutritional Status ,Breast Neoplasms ,Body Mass Index ,Europe ,Receptors, Estrogen ,25-hydroxyvitamin D ,breast cancer ,estrogen receptor status ,prospective study ,vitamin D ,Risk Factors ,Case-Control Studies ,Body Composition ,Humans ,Female ,Prospective Studies ,ddc:610 ,Vitamin D - Abstract
Experimental evidence suggests that vitamin D might play a role in the development of breast cancer. Although the results of case-control studies indicate that circulating 25-hydroxyvitamin D [25(OH)D] is inversely associated with the risk of breast cancer, the results of prospective studies are inconsistent. A case-control study embedded in the European Prospective Investigation into Cancer and Nutrition (EPIC) was carried out comprising 1,391 incident breast cancer cases and 1,391 controls. Multivariable conditional logistic regression models did not reveal a significant overall association between season-standardized 25(OH)D levels and the risk of breast cancer (ORQ4-Q1 [95% CI]: 1.07 [0.85-1.36], ptrend = 0.67). Moreover, 25(OH)D levels were not related to the risks of estrogen receptor positive tumors (ORQ4-Q1 [95% CI]: 0.97 [0.67-1.38], p trend = 0.90) and estrogen receptor negative tumors (OR Q4-Q1 [95% CI]: 0.97 [0.66-1.42], ptrend = 0.98). In hormone replacement therapy (HRT) users, 25(OH)D was significantly inversely associated with incident breast cancer (ORlog2 [95% CI]: 0.62 [0.42-0.90], p = 0.01), whereas no significant association was found in HRT nonusers (ORlog2 [95% CI]: 1.14 [0.80-1.62], p = 0.48). Further, a nonsignificant inverse association was found in women with body mass indices (BMI) < 25 kg/m2 (ORlog2 [95% CI]: 0.83 [0.67-1.03], p = 0.09), as opposed to a borderline significant positive association in women with BMI ≥ 25 kg/m2 (ORlog2 [95% CI]: 1.30 [1.0-1.69], p = 0.05). Overall, prediagnostic levels of circulating 25(OH)D were not related to the risk of breast cancer in the EPIC study. This result is in line with findings in the majority of prospective studies and does not support a role of vitamin D in the development of breast cancer. What's new? Experimental studies have indicated that vitamin D may play a role in preventing tumor formation in the breast. However, in the present investigation, the largest prospective case-control study on circulating 25-hydroxyvitamin D (25(OH)D) and breast cancer risk conducted to date, pre-diagnostic levels of 25(OH)D were found to be unrelated to overall breast cancer risk. While the results support those of similar prospective studies, a significant inverse association was detected between 25(OH)D levels and incident breast cancer in women taking hormone replacement therapy, suggesting that background factors may influence risk associations. © 2013 UICC.
- Published
- 2013
81. Physical activity and risk of breast cancer overall and by hormone receptor status: The European prospective investigation into cancer and nutrition
- Author
-
Steindorf, K. Ritte, R. Eomois, P.-P. Lukanova, A. Tjonneland, A. Johnsen, N.Fø. Overvad, K. Østergaard, J.N. Clavel-Chapelon, F. Fournier, A. Dossus, L. Teucher, B. Rohrmann, S. Boeing, H. Wientzek, A. Trichopoulou, A. Karapetyan, T. Trichopoulos, D. Masala, G. Berrino, F. Mattiello, A. Tumino, R. Ricceri, F. Quirõs, J.R. Travier, N. Sánchez, M.-J. Navarro, C. Ardanaz, E. Amiano, P. Bueno-De-Mesquita, H.B. Van Duijnhoven, F. Monninkhof, E. May, A.M. Khaw, K.-T. Wareham, N. Key, T.J. Travis, R.C. Borch, K.B. Sund, M. Andersson, A. Fedirko, V. Rinaldi, S. Romieu, I. Wahrendorf, J. Riboli, E. Kaaks, R.
- Abstract
Physical activity is associated with reduced risks of invasive breast cancer. However, whether this holds true for breast cancer subtypes defined by the estrogen receptor (ER) and the progesterone receptor (PR) status is controversial. The study included 257,805 women from the multinational EPIC-cohort study with detailed information on occupational, recreational and household physical activity and important cofactors assessed at baseline. During 11.6 years of median follow-up, 8,034 incident invasive breast cancer cases were identified. Data on ER, PR and combined ER/PR expression were available for 6,007 (67.6%), 4,814 (54.2%) and 4,798 (53.9%) cases, respectively. Adjusted hazard ratios (HR) were estimated by proportional hazards models. Breast cancer risk was inversely associated with moderate and high levels of total physical activity (HR = 0.92, 95% confidence interval (CI): 0.86-0.99, HR = 0.87, 95%-CI: 0.79-0.97, respectively; p-trend = 0.002), compared to the lowest quartile. Among women diagnosed with breast cancer after age 50, the largest risk reduction was found with highest activity (HR = 0.86, 95%-CI: 0.77-0.97), whereas for cancers diagnosed before age 50 strongest associations were found for moderate total physical activity (HR = 0.78, 95%-CI: 0.64-0.94). Analyses by hormone receptor status suggested differential associations for total physical activity (p-heterogeneity = 0.04), with a somewhat stronger inverse relationship for ER+/PR+ breast tumors, primarily driven by PR+ tumors (p-heterogeneity < 0.01). Household physical activity was inversely associated with ER-/PR- tumors. The results of this largest prospective study on the protective effects of physical activity indicate that moderate and high physical activity are associated with modest decreased breast cancer risk. Heterogeneities by receptor status indicate hormone-related mechanisms. What's new? Physical activity is associated with a reduced risk of breast cancer, but whether this holds true for hormone receptor-positive cancers, the most common breast cancer subtypes, is controversial. In this analysis of more than 8,000 breast cancer cases, positive receptor status for estrogen and progesterone was inversely associated with moderate and high physical activity. While benefits were modest, the data suggest that the adoption of even moderate activity levels in high-risk populations could reduce breast cancer incidence. Copyright © 2012 UICC.
- Published
- 2013
82. The association of circulating adiponectin levels with pancreatic cancer risk: A study within the prospective EPIC cohort
- Author
-
Grote, V.A. Rohrmann, S. Dossus, L. Nieters, A. Halkjær, J. Tjønneland, A. Overvad, K. Stegger, J. Chabbert-Buffet, N. Boutron-Ruault, M.-C. Clavel-Chapelon, F. Teucher, B. Becker, S. Montonen, J. Boeing, H. Trichopoulou, A. Lagiou, P. Trichopoulos, D. Palli, D. Sieri, S. Tumino, R. Vineis, P. Mattiello, A. Argüelles, M. Duell, E.J. Molina-Montes, E. Larrañaga, N. Chirlaque, M.-D. Gurrea, A.B. Jeurnink, S.M. Peeters, P.H.M. Ye, W. Sund, M. Lindkvist, B. Johansen, D. Khaw, K.-T. Wareham, N. Crowe, F.L. Romieu, I. Rinaldi, S. Jenab, M. Romaguera, D. Michaud, D.S. Riboli, E. Bas Bueno-De-Mesquita, H. Kaaks, R.
- Abstract
Excess body weight and type 2 diabetes mellitus, risk factors of pancreatic cancer, are characterized by decreased levels of adiponectin. In addition to anti-inflammatory and anti-proliferative actions, adiponectin has an important role in regulating glucose metabolism, i.e., decreasing circulating blood glucose levels. Prospectively, hyperglycemia has been associated with risk of pancreatic cancer. The aim of this study was to investigate the association of pre-diagnostic adiponectin levels with pancreatic cancer risk. We conducted a case-control study nested within European Prospective Investigation into Cancer and Nutrition. Blood samples of 452 pancreatic cancer cases and 452 individually matched controls were analyzed by immunoassays. Multivariate conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Overall, adiponectin showed no association with pancreas cancer risk; however, among never smokers, higher circulating levels of adiponectin were associated with a reduction in pancreatic cancer risk (OR = 0.44 [95% CI 0.23-0.82] for highest vs. lowest quartile), whereas among current smokers there was no significant association (OR = 1.59 [95% CI 0.67-3.76] for highest vs. lowest quartile; p-trend = 0.530; p-interaction = 0.309). In our study, lower adiponectin concentrations may be associated with the development of pancreatic cancer among never smokers, whereas the only other prospective study being conducted so far showed a decrease in risk among male smokers. Therefore, further studies are needed to clarify the role of adiponectin in pancreatic cancer development. © 2011 UICC.
- Published
- 2012
83. Prospective study on physical activity and risk of in situ breast cancer
- Author
-
Steindorf, K. Ritte, R. Tjonneland, A. Johnsen, N.F. Overvad, K. Østergaard, J.N. Clavel-Chapelon, F. Fournier, A. Dossus, L. Lukanova, A. Chang-Claude, J. Boeing, H. Wientzek, A. Trichopoulou, A. Karapetyan, T. Trichopoulos, D. Masala, G. Krogh, V. Mattiello, A. Tumino, R. Polidoro, S. Quirós, J.R. Travier, N. Sánchez, M.-J. Navarro, C. Ardanaz, E. Amiano, P. Bueno-de-Mesquita, H.B. Van Duijnhoven, F.J.B. Monninkhof, E. May, A.M. Khaw, K.-T. Wareham, N. Key, T.J. Travis, R.C. Borch, K.B. Fedirko, V. Rinaldi, S. Romieu, I. Wark, P.A. Norat, T. Riboli, E. Kaaks, R.
- Abstract
Background: Physical activity has been identified as protective factor for invasive breast cancer risk, whereas comparable studies on in situ carcinoma are rare. Methods: The study included data from 283,827 women of the multinational European Prospective Investigation into C7ancer and Nutrition (EPIC)-cohort study. Detailed information on different types of physical activity conducted during the prior year, such as occupational, recreational, and household activity, as well as on important cofactors, was assessed at baseline. Adjusted HRs for in situ breast cancer were estimated by Cox proportional hazards models. Results: During a median follow-up period of 11.7 years, 1,059 incidents of breast carcinoma in situ were identified. In crude and adjusted multivariable models, no associations were found for occupational, household, and recreational physical activity. Furthermore, total physical activity was not associated with risk of in situ breast cancer. Comparing moderately inactive, moderately active, and active participants with inactive study participants resulted in adjusted HRs of 0.99 [95% confidence interval (CI), 0.83-1.19], 0.99 (95% CI, 0.82-1.20), and 1.07 (95% CI, 0.81-1.40), respectively (P value of trend test: 0.788). No inverse associations were found in any substrata defined by age at diagnosis or body mass index (BMI) status. Conclusions: In this large prospective study, we did not find any evidence of an association between physical activity and in situ breast cancer risk. If not by chance, the contrast between our results for carcinoma in situ and the recognized inverse association for invasive breast cancer suggests that physical activity may have stronger effects on proliferation and late stage carcinogenesis. ©2012 AACR.
- Published
- 2012
84. Sources of pre-analytical variations in yield of DNA extracted from blood samples: Analysis of 50,000 DNA samples in EPIC
- Author
-
Caboux, E. Lallemand, C. Ferro, G. Hémon, B. Mendy, M. Biessy, C. Sims, M. Wareham, N. Britten, A. Boland, A. Hutchinson, A. Siddiq, A. Vineis, P. Riboli, E. Romieu, I. Rinaldi, S. Gunter, M.J. Peeters, P.H.M. van der Schouw, Y.T. Travis, R. Bueno-de-Mesquita, H.B. Canzian, F. Sánchez, M.-J. Skeie, G. Olsen, K.S. Lund, E. Bilbao, R. Sala, N. Barricarte, A. Palli, D. Navarro, C. Panico, S. Redondo, M.L. Polidoro, S. Dossus, L. Boutron-Ruault, M.C. Clavel-Chapelon, F. Trichopoulou, A. Trichopoulos, D. Lagiou, P. Boeing, H. Fisher, E. Tumino, R. Agnoli, C. Hainaut, P.
- Abstract
The European Prospective Investigation into Cancer and nutrition (EPIC) is a long-term, multi-centric prospective study in Europe investigating the relationships between cancer and nutrition. This study has served as a basis for a number of Genome-Wide Association Studies (GWAS) and other types of genetic analyses. Over a period of 5 years, 52,256 EPIC DNA samples have been extracted using an automated DNA extraction platform. Here we have evaluated the pre-analytical factors affecting DNA yield, including anthropometric, epidemiological and technical factors such as center of subject recruitment, age, gender, body-mass index, disease case or control status, tobacco consumption, number of aliquots of buffy coat used for DNA extraction, extraction machine or procedure, DNA quantification method, degree of haemolysis and variations in the timing of sample processing. We show that the largest significant variations in DNA yield were observed with degree of haemolysis and with center of subject recruitment. Age, gender, body-mass index, cancer case or control status and tobacco consumption also significantly impacted DNA yield. Feedback from laboratories which have analyzed DNA with different SNP genotyping technologies demonstrate that the vast majority of samples (approximately 88%) performed adequately in different types of assays. To our knowledge this study is the largest to date to evaluate the sources of pre-analytical variations in DNA extracted from peripheral leucocytes. The results provide a strong evidence-based rationale for standardized recommendations on blood collection and processing protocols for large-scale genetic studies. © 2012 Caboux et al.
- Published
- 2012
85. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition
- Author
-
Tsilidis, K. K. Allen, N. E. Key, T. J. Dossus, L. and Lukanova, A. Bakken, K. Lund, E. Fournier, A. Overvad, K. Hansen, L. Tjonneland, A. Fedirko, V. Rinaldi, S. and Romieu, I. Clavel-Chapelon, F. Engel, P. Kaaks, R. and Schuetze, M. Steffen, A. Bamia, C. Trichopoulou, A. and Zylis, D. Masala, G. Pala, V. Galasso, R. Tumino, R. and Sacerdote, C. Bueno-de-Mesquita, H. B. van Duijnhoven, F. J. B. and Braem, M. G. M. Onland-Moret, N. C. Gram, I. T. and Rodriguez, L. Travier, N. Sanchez, M-J Huerta, J. M. and Ardanaz, E. Larranaga, N. Jirstrom, K. Manjer, J. Idahl, A. Ohlson, N. Khaw, K-T Wareham, N. Mouw, T. Norat, T. Riboli, E.
- Abstract
BACKGROUND: It is well established that parity and use of oral contraceptives reduce the risk of ovarian cancer, but the associations with other reproductive variables are less clear. METHODS: We examined the associations of oral contraceptive use and reproductive factors with ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 327 396 eligible women, 878 developed ovarian cancer over an average of 9 years. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard models stratified by centre and age, and adjusted for smoking status, body mass index, unilateral ovariectomy, simple hysterectomy, menopausal hormone therapy, and mutually adjusted for age at menarche, age at menopause, number of full-term pregnancies and duration of oral contraceptive use. RESULTS: Women who used oral contraceptives for 10 or more years had a significant 45% (HR, 0.55; 95% CI, 0.41-0.75) lower risk compared with users of 1 year or less (P-trend, 52 vs
- Published
- 2011
86. Ожирение, провоспалительные маркеры и риск рака эндометрия: проспективное исследование случай-контроль
- Author
-
Dossus, L., Rinaldi, S., Becker, S., Lukanova, A., and Et, Al
- Published
- 2011
87. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
- Author
-
Grote, V. A. Rohrmann, S. Nieters, A. Dossus, L. and Tjonneland, A. Halkjaer, J. Overvad, K. Fagherazzi, G. and Boutron-Ruault, M. C. Morois, S. Teucher, B. Becker, S. and Sluik, D. Boeing, H. Trichopoulou, A. Lagiou, P. and Trichopoulos, D. Palli, D. Pala, V. Tumino, R. Vineis, P. Panico, S. Rodriguez, L. Duell, E. J. Molina-Montes, E. Dorronsoro, M. Huerta, J. M. Ardanaz, E. Jeurnink, S. M. Beulens, J. W. J. Peeters, P. H. M. Sund, M. Ye, W. and Lindkvist, B. Johansen, D. Khaw, K. T. Wareham, N. and Allen, N. Crowe, F. Jenab, M. Romieu, I. Michaud, D. S. and Riboli, E. Romaguera, D. Bueno-de-Mesquita, H. B. Kaaks, R.
- Abstract
Aims/hypothesis There has been long-standing debate about whether diabetes is a causal risk factor for pancreatic cancer or a consequence of tumour development. Prospective epidemiological studies have shown variable relationships between pancreatic cancer risk and blood markers of glucose and insulin metabolism, overall and as a function of lag times between marker measurements (blood donation) and date of tumour diagnosis. Methods Pre-diagnostic levels of HbA(1c) and C-peptide were measured for 466 participants with pancreatic cancer and 466 individually matched controls within the European Prospective Investigation into Cancer and Nutrition. Conditional logistic regression models were used to estimate ORs for pancreatic cancer. Results Pancreatic cancer risk gradually increased with increasing pre-diagnostic HbA(1c) levels up to an OR of 2.42 (95% CI 1.33, 4.39 highest [>= 6.5%, 48 mmol/mol] vs lowest [
- Published
- 2011
88. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk; a study within the prospective EPIC cohort
- Author
-
Grote, VA, Rohrmann, S, Nieters, A, Dossus, L, Bueno-de-Mesquita, HB, and Kaaks, R
- Subjects
ddc: 610 ,diabetes ,pancreatic cancer ,cohort study ,glycated haemoglobin ,C-peptide ,610 Medical sciences ,Medicine ,EPIC - Abstract
Background: It is a long-standing debate whether diabetes mellitus is a potentially causal risk factor for pancreatic cancer, or more likely a consequence of pancreatic tumour development. Prospective epidemiologic studies have shown variable relationships of pancreas cancer risk with pre-diagnostic[for full text, please go to the a.m. URL], Mainz//2011; 56. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (gmds), 6. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi)
- Published
- 2011
- Full Text
- View/download PDF
89. Diabetes and Onset of Natural Menopause
- Author
-
Brand, J. S., primary, Onland-Moret, N. C., additional, Eijkemans, M. J. C., additional, Tjønneland, A., additional, Roswall, N., additional, Overvad, K., additional, Fagherazzi, G., additional, Clavel-Chapelon, F., additional, Dossus, L., additional, Lukanova, A., additional, Grote, V., additional, Bergmann, M. M., additional, Boeing, H., additional, Trichopoulou, A., additional, Tzivoglou, M., additional, Trichopoulos, D., additional, Grioni, S., additional, Mattiello, A., additional, Masala, G., additional, Tumino, R., additional, Vineis, P., additional, Bueno-de-Mesquita, H. B., additional, Weiderpass, E., additional, Redondo, M. L., additional, Sánchez, M. J., additional, Huerta Castaño, J. M., additional, Arriola, L., additional, Ardanaz, E., additional, Duell, E. J., additional, Rolandsson, O., additional, Franks, P. W., additional, Butt, S., additional, Nilsson, P., additional, Khaw, K. T., additional, Wareham, N., additional, Travis, R., additional, Romieu, I., additional, Gunter, M. J., additional, Riboli, E., additional, and van der Schouw, Y. T., additional
- Published
- 2015
- Full Text
- View/download PDF
90. An epidemiologic risk prediction model for ovarian cancer in Europe: the EPIC study
- Author
-
Li, K, primary, Hüsing, A, additional, Fortner, R T, additional, Tjønneland, A, additional, Hansen, L, additional, Dossus, L, additional, Chang-Claude, J, additional, Bergmann, M, additional, Steffen, A, additional, Bamia, C, additional, Trichopoulos, D, additional, Trichopoulou, A, additional, Palli, D, additional, Mattiello, A, additional, Agnoli, C, additional, Tumino, R, additional, Onland-Moret, N C, additional, Peeters, P H, additional, Bueno-de-Mesquita, H B(as), additional, Gram, I T, additional, Weiderpass, E, additional, Sánchez-Cantalejo, E, additional, Chirlaque, M-D, additional, Duell, E J, additional, Ardanaz, E, additional, Idahl, A, additional, Lundin, E, additional, Khaw, K-T, additional, Travis, R C, additional, Merritt, M A, additional, Gunter, M J, additional, Riboli, E, additional, Ferrari, P, additional, Terry, K, additional, Cramer, D, additional, and Kaaks, R, additional
- Published
- 2015
- Full Text
- View/download PDF
91. Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort
- Author
-
Ose, J, primary, Fortner, R T, additional, Schock, H, additional, Peeters, P H, additional, Onland-Moret, N C, additional, Bueno-de-Mesquita, H B, additional, Weiderpass, E, additional, Gram, I T, additional, Overvad, K, additional, Tjonneland, A, additional, Dossus, L, additional, Fournier, A, additional, Baglietto, L, additional, Trichopoulou, A, additional, Benetou, V, additional, Trichopoulos, D, additional, Boeing, H, additional, Masala, G, additional, Krogh, V, additional, Matiello, A, additional, Tumino, R, additional, Popovic, M, additional, Obón-Santacana, M, additional, Larrañaga, N, additional, Ardanaz, E, additional, Sánchez, M-J, additional, Menéndez, V, additional, Chirlaque, M-D, additional, Travis, R C, additional, Khaw, K-T, additional, Brändstedt, J, additional, Idahl, A, additional, Lundin, E, additional, Rinaldi, S, additional, Kuhn, E, additional, Romieu, I, additional, Gunter, M J, additional, Merritt, M A, additional, Riboli, E, additional, and Kaaks, R, additional
- Published
- 2014
- Full Text
- View/download PDF
92. Erratum: Lifestyle factors and serum androgens among 636 middle aged men from seven countries in the European prospective investigation into cancer and nutrition (EPIC) (Cancer Causes Control DOI: 10.1007/s10552-009-9326-y)
- Author
-
Suzuki, R, Allen, NE, Appleby, PN, Key, TJ, Dossus, L, Tjønneland, A, Føns Johnsen, N, Overvad, K, Sacerdote, C, Palli, D, Krogh, V, Tumino, R, Rohrmann, S, Linseisen, J, Boeing, H, Trichopoulou, A, Makrygiannis, G, Misirli, G, Bueno-De-Mesquita, HB, May, AM, Díaz, MJT, Sánchez, M-J, Barricarte Gurrea, A, Rodríguez Suárez, L, Buckland, G, Larrañaga, N, Bingham, S, Khaw, K-T, Rinaldi, S, Slimani, N, Jenab, M, Riboli, E, and Kaaks, R
- Published
- 2009
93. Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)
- Author
-
Canzian, F. Kaaks, R. Cox, D.G. Henderson, K.D. Henderson, B.E. Berg, C. Bingham, S. Boeing, H. Buring, J. Calle, E.E. Chanock, S. Clavel-Chapelon, F. Dossus, L. Feigelson, H.S. Haiman, C.A. Hankinson, S.E. Hoover, R. Hunter, D.J. Isaacs, C. Lenner, P. Lund, E. Overvad, K. Palli, D. Pearce, C.L. Quiros, J.R. Riboli, E. Stram, D.O. Thomas, G. Thun, M.J. Trichopoulos, D. van Gils, C.H. Ziegler, R.G.
- Abstract
Background: Gonadotropin releasing hormone (GNRH1) triggers the release of follicle stimulating hormone and luteinizing hormone from the pituitary. Genetic variants in the gene encoding GNRH1 or its receptor may influence breast cancer risk by modulating production of ovarian steroid hormones. We studied the association between breast cancer risk and polymorphisms in genes that code for GNRH1 and its receptor (GNRHR) in the large National Cancer Institute Breast and Prostate Cancer Cohort Consortium (NCI-BPC3). Methods: We sequenced exons of GNRH1 and GNRHR in 95 invasive breast cancer cases. Resulting single nucleotide polymorphisms (SNPs) were genotyped and used to identify haplotype-tagging SNPs (htSNPS) in a panel of 349 healthy women. The htSNPs were genotyped in 5,603 invasive breast cancer cases and 7,480 controls from the Cancer Prevention Study-II (CPS-II), European Prospective Investigation on Cancer and Nutrition (EPIC), Multiethnic Cohort (MEC), Nurses' Health Study (NHS), and Women's Health Study (WHS). Circulating levels of sex steroids (androstenedione, estradiol, estrone and testosterone) were also measured in 4713 study subjects. Results: Breast cancer risk was not associated with any polymorphism or haplotype in the GNRH1 and GNRHR genes, nor were there any statistically significant interactions with known breast cancer risk factors. Polymorphisms in these two genes were not strongly associated with circulating hormone levels. Conclusion: Common variants of the GNRH1 and GNRHR genes are not associated with risk of invasive breast cancer in Caucasians. © 2009 Canzian et al; licensee BioMed Central Ltd.
- Published
- 2009
94. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC)
- Author
-
Allen, N.E. Key, T.J. Dossus, L. Rinaldi, S. Cust, A. Lukanova, A. Peeters, P.H. Onland-Moret, N.C. Lahmann, P.H. Berrino, F. Panico, S. Larrahaga, N. Pera, G. Tormo, M.-J. Sánchez, M.-J. Quirós, J.R. Ardanaz, E. Tjønneland, A. Olsen, A. Chang-Claude, J. Linseisen, J. Schulz, M. Boeing, H. Lundin, E. Palli, D. Overvad, K. Clavel-Chapelon, F. Boutron-Ruault, M.-C. Bingham, S. Khaw, K.-T. Bueno-De-Mesquita, H.B. Trichopoulou, A. Trichopoulos, D. Naska, A. Tumino, R. Riboli, B. Kaaks, R.
- Abstract
Epidemiological data show that reproductive and hormonal factors are involved in the etiology of endometrial cancer, but there is little data on the association with endogenous sex hormone levels. We analyzed the association between prediagnostic serum concentrations of sex steroids and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition using a nested case-control design of 247 incident endometrial cancer cases and 481 controls, matched on center, menopausal status, age, variables relating to blood collection, and, for premenopausal women, phase of menstrual cycle. Using conditional regression analysis, endometrial cancer risk among postmenopausal women was positively associated with increasing levels of total testosterone, free testosterone, estrone, total estradiol, and free estradiol. The odds ratios (ORs) for the highest versus lowest fertile were 2.66 (95% confidence interval (CI) 1.50-4.72; P=0.002 for a continuous linear trend) for estrone, 2.07 (95% CI 1.20-3.60; P = 0.001) for estradiol, and 1.66 (95% CI 0.98-2.82; P = 0.001) for free estradiol. For total and free testosterone, ORs for the highest versus lowest fertile were 1.44 (95% CI 0.88-2.36; P = 0.05) and 2.05 (95% CI 1.23-3.42; P = 0.005) respectively. Androstenedione and dehydroepiandrosterone sulfate were not associated with risk. Sex hormone-binding globulin was significantly inversely associated with risk (OR for the highest versus lowest fertile was 0.57, 95% CI 0.34-0.95; P = 0.004). In premenopausal women, serum sex hormone concentrations were not clearly associated with endometrial cancer risk, but numbers were too small to draw firm conclusions. In conclusion, relatively high blood concentrations of estrogens and free testosterone are associated with an increased endometrial cancer risk in postmenopausal women. © 2008 Society for Endocrinology.
- Published
- 2008
95. Haplotype-based analysis of common variation in the acetyl-CoA carboxylase α gene and breast cancer risk: A case-control study nested within the European Prospective Investigation into Cancer and Nutrition
- Author
-
Sinilnikova, O.M. McKay, J.D. Tavtigian, S.V. Canzian, F. DeSilva, D. Biessy, C. Monnier, S. Dossus, L. Boillot, C. Gioia, L. Hughes, D.J. Jensen, M.K. Overvad, K. Tjonneland, A. Olsen, A. Clavel-Chapelon, F. Chajès, V. Joulin, V. Linseisen, J. Chang-Claude, J. Boeing, H. Dahm, S. Trichopoulou, A. Trichopoulos, D. Koliva, M. Khaw, K.-T. Bingham, S. Allen, N.E. Key, T. Palli, D. Panico, S. Berrino, F. Tumino, R. Vineis, P. Bueno-de-Mesquita, H.B. Peeters, P.H. Van Gils, C.H. Lund, E. Pera, G. Quirós, J.R. Dorronsoro, M. García, C.M. Tormo, M.-J. Ardanaz, E. Hallmans, G. Lenner, P. Berglund, G. Manjer, J. Riboli, E. Lenoir, G.M. Kaaks, R.
- Abstract
A key fatty acid synthesis enzyme, acetyl-CoA carboxylase α. (ACC-α), has been shown to be highly expressed in human breast cancer and other tumor types and also to specifically interact with the protein coded by one of two major breast cancer susceptibility genes BRCA1. We used a comprehensive haplotype analysis to examine the contribution of the ACC-α common genetic variation (allele frequency >5%) to breast cancer in a case-control study (1,588 cases/2,600 controls) nested within the European Prospective Investigation into Cancer and Nutrition. We identified 21 haplotype-tagging polymorphisms efficiently capturing common variation within 325 kb of ACC-α and surrounding sequences using genotype data from the HapMap project and our resequencing data. We found an effect on overall risk of breast cancer in homozygous carriers of one common haplotype [odds ratio (OR), 1.74; 95% confidence interval (95% CI), 1.03-2.94]. When the data were subdivided by menopausal status, we found statistical evidence of heterogeneity for two other common haplotypes (P value for heterogeneity = 0.016 and 0.045). In premenopausal women, the carriers of these haplotypes, compared with noncarriers, had an altered risk of breast cancer (OR, 0.70; 95% CI, 0.53-0.92 and OR, 1.35; 95% CI, 1.04-1.76). These findings were not significant after adjustment for multiple testing and therefore should be considered as preliminary and evaluated in larger independent studies. However, they suggest a possible role of the ACC-α common sequence variants in susceptibility to breast cancer and encourage studies of other genes involved in fatty acid synthesis. Copyright © 2007 American Association for Cancer Research.
- Published
- 2007
96. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women
- Author
-
Haiman, C.A. Dossus, L. Setiawan, V.W. Stram, D.O. Dunning, A.M. Thomas, G. Thun, M.J. Albanes, D. Altshuler, D. Ardanaz, E. Boeing, H. Buring, J. Burtt, N. Calle, E.E. Chanock, S. Clavel-Chapelon, F. Colditz, G.A. Cox, D.G. Feigelson, H.S. Hankinson, S.E. Hayes, R.B. Henderson, B.E. Hirschhorn, J.N. Hoover, R. Hunter, D.J. Kaaks, R. Kolonel, L.N. Le Marchand, L. Lenner, P. Lund, E. Panico, S. Peeters, P.H. Pike, M.C. Riboli, E. Tjonneland, A. Travis, R. Trichopoulos, D. Wacholder, S. Ziegler, R.G.
- Abstract
The CTP19A1 gene encodes the enzyme aromatase, which is responsible for the final step in the biosynthesis of estrogens. In this study, we used a systematic two-step approach that included gene resequencing and a haplotype-based analysis to comprehensively survey common genetic variation across the CYP19A1 locus in relation to circulating postmenopausal steroid hormone levels and breast cancer risk. This study was conducted among 5,356 invasive breast cancer cases and 7,129 controls comprised primarily of White women of European descent drawn from five large prospective cohorts within the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. A high-density single-nucleotide polymorphism (SNP) map of 103 common SNPs (≥5% frequency) was used to identify the linkage disequilibrium and haplotype patterns across the CYP19A1 locus, and 19 haplotype-tagging SNPs were selected to provide high predictability of the common haplotype patterns. We found haplotype-tagging SNPs and common haplotypes spanning the coding and proximal 5′ region of CYP19A1 to be significantly associated with a 10% to 20% increase in endogenous estrogen levels in postmenopausal women [effect per copy of the two-SNP haplotype rs749292-rs727479 (A-A) versus noncarriers; P = 4.4 × 10-15]. No significant associations were observed, however, with these SNPs or common haplotypes and breast cancer risk. Thus, although genetic variation in CYP19A1 produces measurable differences in estrogen levels among postmenopausal women, the magnitude of the change was insufficient to contribute detectably to breast cancer. ©2007 American Association for Cancer Research.
- Published
- 2007
97. Plasma adiponectin levels and endometrial cancer risk in pre- and post-menopausal women
- Author
-
Ae, Cust, Kaaks, R., Friedenreich, C., Bonnet, F., Laville, M., Lukanova, A., Rinaldi, S., Dossus, L., Slimani, N., Lundin, E., Anne Tjønneland, Anja Viendahl Olsen, Kim Overvad, Clavel-Chapelon, F., Mesrine, S., Joulin, V., Linseisen, J., Rohrmann, S., Pischon, T., Boeing, H., Trichopoulos, D., Trichopoulou, A., Benetou, V., Palli, D., Berrino, F., Tumino, R., Sacerdote, C., Mattiello, A., Jr, Quirós, Ma, Mendez, M-J, Sánchez, Larranaga, N., Mj, Tormo, Ardanaz, E., Hb, Bueno-De-Mesquita, Phm, Peeters, Ch, Gils, K-T, Khaw, Bingham, S., Allen, N., Key, T., Jenab, M., and Riboli, E.
- Published
- 2007
98. Risk of endometrial cancer in relationship to cigarette smoking: Results from the EPIC study
- Author
-
Al-Zoughool, M. Dossus, L. Kaaks, R. Clavel-Chapelon, F. Tjønneland, A. Olsen, A. Overvad, K. Boutron-Ruault, M.-C. Gauthier, E. Linseisen, J. Chang-Claude, J. Boeing, H. Schulz, M. Trichopoulou, A. Chryssa, T. Trichopoulos, D. Berrino, F. Palli, D. Mattiello, A. Tumino, R. Sacerdote, C. Bueno-de-Mesquita, H.B. Boshuizen, H.C. Peeters, P.H.M. Gram, I.T. Braaten, T. Lund, E. Chirlaque, M.-D. Ardanaz, E. Agudo, A. Larrañaga, N. Quirós, J.R. Berglund, G. Manjer, J. Lundin, E. Hallmans, G. Khaw, K.-T. Bingham, S. Allen, N. Key, T. Jenab, M. Cust, A.E. Rinaldi, S. Riboli, E.
- Abstract
Current epidemiologic evidence indicates that cigarette smoking reduces the risk of endometrial cancer. We examined data from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort to analyze further aspects of the smoking-endometrial cancer relationship, such as possible modifying effects of menopausal status, HRT use, BMI and parity. In a total of 249,986 women with smoking exposure and menopausal status information, 619 incident endometrial cancer cases were identified during 1.56 million person-years of follow-up. Among postmenopausal women, the hazard ratio (HR) for current smokers versus never smokers was 0.70 (95% CI = 0.53-0.93), while it was 1.75 (95% CI = 1.13-2.70) among premenopausal women at recruitment. After adjustment for risk factors, the HR for postmenopausal women was slightly attenuated to 0.78 (95% CI = 0.59-1.03). No heterogeneity of effect was observed with HRT use or BMI. Among premenopausal women, current smokers of more than 15 cigarettes per day or who smoked for 30 years or more at the time of recruitment had a more than 2-fold increased risk of endometrial cancer compared to never smokers (HR = 2.54; 95% CI = 1.47-4.38 and HR = 2.23; 95% CI = 1.04-4.77, respectively). Past smoking was not associated with endometrial cancer risk, either among pre- or post-menopausal women. In this prospective study, we observed an increased risk of endometrial cancer with cigarette smoking in premenopausal women. The reduction of endometrial cancer risk observed among postmenopausal women does not have direct public health relevance since cigarette smoking is the main known risk factor for cancer. © 2007 Wiley-Liss, Inc.
- Published
- 2007
99. Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women
- Author
-
Norat, T. Dossus, L. Rinaldi, S. Overvad, K. Grønbæk, H. Tjønneland, A. Olsen, A. Clavel-Chapelon, F. Boutron-Ruault, M.C. Boeing, H. Lahmann, P.H. Linseisen, J. Nagel, G. Trichopoulou, A. Trichopoulos, D. Kalapothaki, V. Sieri, S. Palli, D. Panico, S. Tumino, R. Sacerdote, C. Bueno-de-Mesquita, H.B. Peeters, P.H.M. van Gils, C.H. Agudo, A. Amiano, P. Ardanoz, E. Martinez, C. Quirós, R. Tormo, M.J. Bingham, S. Key, T.J. Allen, N.E. Ferrari, P. Slimani, N. Riboli, E. Kaaks, R.
- Abstract
Objective: The aim of this study was to examine the relationship of diet with serum insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 in women. Design: Cross-sectional study. Setting and subjects: The population are 2109 women who were control subjects in a case-control study of breast cancer nested in the European Prospective Investigation into Cancer and Nutrition. Control subjects were randomly chosen among risk sets consisting of female cohort members alive and free of cancer (except non-melanoma skin cancer) at the time of diagnosis of the index case. Matching criteria were age at enrolment, follow-up time, time of the day of blood collection and study centre. Diet was measured through validated questionnaires. Serum hormone concentrations were measured by enzyme-linked immunosorbent assays. The relationship between serum IGF-I, IGFBP-3, and intake of nutrients and foods was explored by linear regression in models adjusted for energy intake, age, body mass index, smoking, physical activity, centre and laboratory batch. Results: Serum IGF-I levels were positively related to protein intake (Ptrend < 0.001), but not related to energy, fat or carbohydrate intake. Positive relationships were observed with the intake of milk (Ptrend = 0.007), calcium (Ptrend < 0.001), magnesium (Ptrend = 0.003), phosphorus (Ptrend < 0.001), potassium (Ptrend = 0.002), vitamin B6 (Ptrend = 0.03), vitamin B2 (Ptrend = 0.001) and inverse relationships with vegetables (Ptrend = 0.02) and beta-carotene (Ptrend = 0.02). IGFBP-3 was not related with most of the nutrients and foods in this study. Conclusions: In this population, circulating IGF-I is modestly related with the intake of protein and minerals, and with milk and cheese, while IGFBP-3 does not appear to be related with diet.
- Published
- 2007
100. IGF-1, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC)
- Author
-
Rinaldi, S. Peeters, P. H. M. Berrino, F. Dossus, L. and Biessy, C. Olsen, A. Tjonneland, A. Overvad, K. and Clavel-Chapelon, F. Boutron-Ruault, M. C. Tehard, B. Nagel, G. Linseisen, J. Boeing, H. Lahmann, P. H. Trichopoulou, A. Trichopoulos, D. Koliva, M. Palli, D. Panico, S. and Tumino, R. Sacerdote, C. van Gils, C. H. van Noord, P. and Grobbee, D. E. Bueno-de-Mesquita, H. B. Gonzalez, C. A. and Agudo, A. Chirlaque, M. D. Barricarte, A. Larranaga, N. and Quiros, J. R. Bingham, S. Khaw, K. T. Key, T. Allen, N. E. Lukanova, A. Slimani, N. Saracci, R. Riboli, E. and Kaaks, R.
- Abstract
Blood concentrations of insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) have recently been associated with breast cancer risk, notably in women who developed breast cancer at a young age. Prospective studies published so far, however, were relatively small and odds ratio (OR) estimates imprecise. We present the results of a large prospective case-control study nested within the European Prospective Investigation into Cancer and Nutrition on total IGIF-I, IGFBP-3 and breast cancer risk including 1081 incident cases of invasive breast cancer and 2098 matched control subjects. Increasing IGF-I and IGFBP-3 concentrations were associated with a significant increase in breast cancer risk in women who developed breast cancer after 50 years of age (highest vs lowest quintile OR 1.38 (95% confidence interval (CI) 1.02-1.86), P = 0.01, and 1.44 (95% CI 1.04-1.98), P = 0.01, respectively), but no relationship was observed in younger women (OR = 1.03 (95% CI 0.60-1.77), P = 0.81 for IGF-I, and OR = 0.92 (95% CI 0.50-1.70), P = 0.69 for IGFBP-3). There was, however, significant heterogeneity in the relationship of breast cancer with serum IGF-I and IGFBP-3 levels depending on the time interval between blood donation and tumor diagnosis. A reduction in breast cancer risk with increasing IGF-I concentrations was observed in cases with a diagnosis of cancer less than 2 years after blood donation, (OR = 0.76 (95% CI 0.57-1.03)), while an increase in risk was observed for women with a later diagnosis (above or equal to two years after blood collection, OR = 1.51 (95% CI 1.19-1.91)). A similar pattern was observed for IGFBP-3. This study confirms previous findings for an association of serum IGF-I and IGFBP-3 concentrations with breast cancer risk, particularly for women with a later diagnosis of cancer, but it does not support the hypothesis of an involvement of IGF-I in younger women.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.